<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36058839</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-4076</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of geriatric oncology</Title><ISOAbbreviation>J Geriatr Oncol</ISOAbbreviation></Journal><ArticleTitle>Change in four measures of physical function among older adults during lung cancer treatment: A mixed methods cohort study.</ArticleTitle><Pagination><StartPage>101366</StartPage><MedlinePgn>101366</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jgo.2022.08.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1879-4068(22)00206-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Functional outcomes during non-small cell lung cancer (NSCLC) treatment are critically important to older adults. Yet, data on physical function and which measures best capture functional change remain limited.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This multisite, mixed methods cohort study recruited adults &#x2265;65&#xa0;years with advanced NSCLC starting systemic treatment (i.e., chemotherapy, immunotherapy, and/or targeted therapy) with non-curative intent. Participants underwent serial geriatric assessments prior to starting treatment and at one, two, four, and six months, which included the Karnofsky Performance Scale (KPS, range: 0-100%), instrumental activities of daily living (IADL, range: 0-14), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Physical Functioning subscale (EORTC QLQ-C30 PF, range: 0-100), and Life-Space Assessment (LSA, range: 0-120). For all measures, higher scores represent better functioning. In a qualitative substudy, 20 patients completed semi-structured interviews prior to starting treatment and at two and six months to explore how treatment affected their daily functioning. We created joint displays for each interview participant that integrated their longitudinal KPS, IADL, EORTC QLQ-C30 PF, and LSA scores with patient quotes describing their function.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 87 patients, median age was 73&#xa0;years (range 65-96). Mean pretreatment KPS score was 79% (standard deviation [SD] 13), EORTC QLQ-C30 PF was 69 (SD 23), and LSA was 67 (SD 28); median IADL was 13 (interquartile range [IQR] 10-14). At two months after treatment initiation, 70% of patients experienced functional decline on at least one measure, with only 13% of these patients recovering at six months. At two and six months, decline in LSA was the most common (48% and 35%, respectively). Joint displays revealed heterogeneity in how well each quantitative measure of physical function captured the qualitative patient experience.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Functional decline during NSCLC treatment is common among older adults. LSA is a useful measure to detect subtle functional decline that may be missed by other measures. Given heterogeneity in how well each quantitative measure captures changes in physical function, there is value to including more than one functional measure in geriatric oncology research studies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singhal</LastName><ForeName>Surbhi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Louise C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Alexander K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loh</LastName><ForeName>Kah Poh</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>James P. Wilmot Cancer Institute, Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Harvey Jay</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Center for the Study of Aging &amp; Human Development and Duke Cancer Institute, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boscardin</LastName><ForeName>W John</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Presley</LastName><ForeName>Carolyn J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Grant R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Divisions of Hematology/Oncology and Gerontology, Geriatrics, and Palliative Care, The University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magnuson</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>James P. Wilmot Cancer Institute, Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohile</LastName><ForeName>Supriya G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>James P. Wilmot Cancer Institute, Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Melisa L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA; Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. Electronic address: melisa.wong@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG068312</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K76 AG064431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG056439</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001872</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG064374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028716</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33 AG059206</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K76 AG064394</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 CA234225</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 CA237744</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR001870</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG044281</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG056589</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Geriatr Oncol</MedlineTA><NlmUniqueID>101534770</NlmUniqueID><ISSNLinking>1879-4068</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemotherapy</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">Instrumental activities of daily living</Keyword><Keyword MajorTopicYN="N">Life-space mobility</Keyword><Keyword MajorTopicYN="N">Lung cancer</Keyword><Keyword MajorTopicYN="N">Older adults</Keyword><Keyword MajorTopicYN="N">Physical function</Keyword><Keyword MajorTopicYN="N">Targeted therapy</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest KPL and MLW reported conflicts of interest outside of the submitted work: KPL has served as a consultant for Pfizer and Seattle Genetics and has received speaker fees from Pfizer. MLW reported that an immediate family member is an employee of Genentech with stock ownership. MLW receives royalties from UpToDate. The remaining authors have no conflicts to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>4</Day><Hour>22</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36058839</ArticleId><ArticleId IdType="mid">NIHMS1835011</ArticleId><ArticleId IdType="pmc">PMC9974579</ArticleId><ArticleId IdType="doi">10.1016/j.jgo.2022.08.015</ArticleId><ArticleId IdType="pii">S1879-4068(22)00206-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605&#x2013;644. doi:10.1016/j.ccm.2011.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccm.2011.09.001</ArticleId><ArticleId IdType="pmc">PMC3864624</ArticleId><ArticleId IdType="pubmed">22054876</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenis C, Decoster L, Bastin J, et al. Functional decline in older patients with cancer receiving chemotherapy: A multicenter prospective study. Journal of Geriatric Oncology. 2017;8(3):196&#x2013;205. doi:10.1016/j.jgo.2017.02.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgo.2017.02.010</ArticleId><ArticleId IdType="pubmed">28330581</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ML, Paul SM, Mastick J, et al. Characteristics Associated With Physical Function Trajectories in Older Adults With Cancer During Chemotherapy. Journal of Pain and Symptom Management. 2018;56(5):678&#x2013;688.e1. doi:10.1016/j.jpainsymman.2018.08.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2018.08.006</ArticleId><ArticleId IdType="pmc">PMC6195841</ArticleId><ArticleId IdType="pubmed">30144536</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhandiramge J, Orchard SG, Warner ET, van Londen GJ, Zalcberg JR. Functional Decline in the Cancer Patient: A Review. Cancers (Basel). 2022;14(6). doi:10.3390/cancers14061368</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14061368</ArticleId><ArticleId IdType="pmc">PMC8946657</ArticleId><ArticleId IdType="pubmed">35326520</ArticleId></ArticleIdList></Reference><Reference><Citation>Decoster L, Kenis C, Schallier D, et al. Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer. Lung. 2017;195(5):619&#x2013;626. doi:10.1007/s00408-017-0025-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-017-0025-2</ArticleId><ArticleId IdType="pubmed">28634893</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger CL, McDonald CF, Irving L, et al. Low physical activity levels and functional decline in individuals with lung cancer. Lung Cancer. 2014;83(2):292&#x2013;299. doi:10.1016/j.lungcan.2013.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2013.11.014</ArticleId><ArticleId IdType="pubmed">24360323</ArticleId></ArticleIdList></Reference><Reference><Citation>Presley CJ, Han L, Leo-Summers L, et al. Functional trajectories before and after a new cancer diagnosis among community-dwelling older adults. J Geriatr Oncol. 2019;10(1):60&#x2013;67. doi:10.1016/j.jgo.2018.05.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgo.2018.05.017</ArticleId><ArticleId IdType="pmc">PMC6526705</ArticleId><ArticleId IdType="pubmed">29937422</ArticleId></ArticleIdList></Reference><Reference><Citation>Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly s. J Clin Oncol. 2005;23(28):6865&#x2013;6872. doi:10.1200/JCO.2005.02.527</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2005.02.527</ArticleId><ArticleId IdType="pubmed">16192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Wedding U, R&#xf6;hrig B, Klippstein A, Brix C, Pientka L, H&#xf6;ffken K. Co-morbidity and functional deficits independently contribute to quality of life before chemotherapy in elderly cancer patients. Support Care Cancer. 2007;15(9):1097&#x2013;1104. doi:10.1007/s00520-007-0228-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-007-0228-9</ArticleId><ArticleId IdType="pubmed">17318590</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried TR, Bradley EH, Towle VR, Allore H. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346(14):1061&#x2013;1066. doi:10.1056/NEJMsa012528</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsa012528</ArticleId><ArticleId IdType="pubmed">11932474</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ML, Shi Y, Smith AK, et al. Changes in older adults&#x2019; life space during lung cancer treatment: A mixed methods cohort study. J Am Geriatr Soc. 2021;(August):1&#x2013;14. doi:10.1111/jgs.17474</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.17474</ArticleId><ArticleId IdType="pmc">PMC8742783</ArticleId><ArticleId IdType="pubmed">34611887</ArticleId></ArticleIdList></Reference><Reference><Citation>Presley CJ, Arrato NA, Shields PG, et al. Functional Trajectories &amp; Resilience among Adults with Advanced Lung Cancer. JTO Clinical and Research Reports. 2022;3(6):100334. doi:10.1016/J.JTOCRR.2022.100334/ATTACHMENT/5D429E7F-99DC-45BB-82D6-93A993175116/MMC1.DOCX</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JTOCRR.2022.100334/ATTACHMENT/5D429E7F-99DC-45BB-82D6-93A993175116/MMC1.DOCX</ArticleId><ArticleId IdType="pmc">PMC9198463</ArticleId><ArticleId IdType="pubmed">35719868</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326&#x2013;2347. doi:10.1200/JCO.2018.78.8687</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2018.78.8687</ArticleId><ArticleId IdType="pmc">PMC6063790</ArticleId><ArticleId IdType="pubmed">29782209</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595&#x2013;2603. doi:10.1200/JCO.2013.54.8347</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2013.54.8347</ArticleId><ArticleId IdType="pmc">PMC4876338</ArticleId><ArticleId IdType="pubmed">25071125</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 1980;45(8):2220&#x2013;2224. doi:10.1002/1097-0142(19800415)45:8&lt;2220::aid-cncr2820450835&gt;3.0.co;2-q</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0142(19800415)45:8&lt;2220::aid-cncr2820450835&gt;3.0.co;2-q</ArticleId><ArticleId IdType="pubmed">7370963</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooks V, Waller S, Smith T, Hahn TJ. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol. 1991;46(4):M139&#x2013;44. doi:10.1093/geronj/46.4.m139</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronj/46.4.m139</ArticleId><ArticleId IdType="pubmed">2071835</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolly TA, Deal AM, Nyrop KA, et al. Geriatric assessment-identified deficits in older cancer patients with normal performance status. Oncologist. 2015;20(4):379&#x2013;385. doi:10.1634/theoncologist.2014-0247</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2014-0247</ArticleId><ArticleId IdType="pmc">PMC4391761</ArticleId><ArticleId IdType="pubmed">25765876</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoppe S, Rainfray M, Fonck M, et al. Functional decline in older patients with cancer receiving first-line chemotherapy. Journal of Clinical Oncology. 2013;31(31):3877&#x2013;3882. doi:10.1200/JCO.2012.47.7430</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2012.47.7430</ArticleId><ArticleId IdType="pubmed">24062399</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365&#x2013;376. doi:10.1093/jnci/85.5.365</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/85.5.365</ArticleId><ArticleId IdType="pubmed">8433390</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh KP, Lam V, Webber K, et al. Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults. J Natl Compr Canc Netw. 2021;19(9):1055&#x2013;1062. doi:10.6004/jnccn.2020.7684</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2020.7684</ArticleId><ArticleId IdType="pmc">PMC8517039</ArticleId><ArticleId IdType="pubmed">33857918</ArticleId></ArticleIdList></Reference><Reference><Citation>Peel C, Sawyer Baker P, Roth DL, Brown CJ, Brodner E v, Allman RM. Assessing mobility in older adults: the UAB Study of Aging Life-Space Assessment. Phys Ther. 2005;85(10):1008&#x2013;1119. http://www.ncbi.nlm.nih.gov/pubmed/16180950</Citation><ArticleIdList><ArticleId IdType="pubmed">16180950</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J, Rodriguez MA, Al Snih S. Life-Space Mobility in the Elderly: Current Perspectives. Clin Interv Aging. 2020;15:1665&#x2013;1674. doi:10.2147/CIA.S196944</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S196944</ArticleId><ArticleId IdType="pmc">PMC7501960</ArticleId><ArticleId IdType="pubmed">32982200</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart CML, Wheeler TL, Markland AD, Straughn JM, Richter HE. Life-space assessment in urogynecology and gynecological oncology surgery patients: a measure of perioperative mobility and function. J Am Geriatr Soc. 2009;57(12):2263&#x2013;2268. doi:10.1111/j.1532-5415.2009.02557.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2009.02557.x</ArticleId><ArticleId IdType="pmc">PMC3252022</ArticleId><ArticleId IdType="pubmed">19874406</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee J, Davis GM, Beith JM, et al. Physical activity and fitness in women with metastatic breast cancer. J Cancer Surviv. 2014;8(4):647&#x2013;656. doi:10.1007/s11764-014-0378-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11764-014-0378-y</ArticleId><ArticleId IdType="pubmed">24986228</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatt&#xe1;s-Vernaglia IF, Ramos PT, Perini MLL, et al. Impact of the COVID-19 pandemic on the life-space mobility of older adults with cancer. J Geriatr Oncol. 2021;12(6):956&#x2013;959. doi:10.1016/j.jgo.2021.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgo.2021.02.012</ArticleId><ArticleId IdType="pmc">PMC7883734</ArticleId><ArticleId IdType="pubmed">33640305</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer AS, Wells JM, Bhatt SP, et al. Life-Space mobility and clinical outcomes in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:2731&#x2013;2738. doi:10.2147/COPD.S170887</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S170887</ArticleId><ArticleId IdType="pmc">PMC6130264</ArticleId><ArticleId IdType="pubmed">30233163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy RE, Williams CP, Sawyer P, et al. Life-Space Predicts Health Care Utilization in Community-Dwelling Older Adults. J Aging Health. 2019;31(2):280&#x2013;292. doi:10.1177/0898264317730487</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0898264317730487</ArticleId><ArticleId IdType="pubmed">29254407</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackey DC, Lui LY, Cawthon PM, Ensrud K, Yaffe K, Cummings SR. Life-Space Mobility and Mortality in Older Women: Prospective Results from the Study of Osteoporotic Fractures. J Am Geriatr Soc. 2016;64(11):2226&#x2013;2234. doi:10.1111/jgs.14474</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.14474</ArticleId><ArticleId IdType="pmc">PMC5118116</ArticleId><ArticleId IdType="pubmed">27696354</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9):1998&#x2013;2005. doi:10.1002/cncr.21422</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.21422</ArticleId><ArticleId IdType="pubmed">16206252</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA. 1963;185:914&#x2013;919. doi:10.1001/jama.1963.03060120024016</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1963.03060120024016</ArticleId><ArticleId IdType="pubmed">14044222</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol. 1981;36(4):428&#x2013;434. doi:10.1093/geronj/36.4.428</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronj/36.4.428</ArticleId><ArticleId IdType="pubmed">7252074</ArticleId></ArticleIdList></Reference><Reference><Citation>Podsiadlo D, Richardson S. The timed &#x201c;Up &amp; Go&#x201d;: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142&#x2013;148. doi:10.1111/j.1532-5415.1991.tb01616.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.1991.tb01616.x</ArticleId><ArticleId IdType="pubmed">1991946</ArticleId></ArticleIdList></Reference><Reference><Citation>Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85&#x2013;94. doi:10.1093/geronj/49.2.m85</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronj/49.2.m85</ArticleId><ArticleId IdType="pubmed">8126356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011;29(10):1290&#x2013;1296. doi:10.1200/JCO.2010.30.6985</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2010.30.6985</ArticleId><ArticleId IdType="pmc">PMC3083997</ArticleId><ArticleId IdType="pubmed">21357782</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohile SG, Epstein RM, Hurria A, et al. Communication With Older Patients With Cancer Using Geriatric Assessment: A Cluster-Randomized Clinical Trial From the National Cancer Institute Community Oncology Research Program. JAMA Oncol. 2020;6(2):196&#x2013;204. doi:10.1001/jamaoncol.2019.4728</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2019.4728</ArticleId><ArticleId IdType="pmc">PMC6865234</ArticleId><ArticleId IdType="pubmed">31697365</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, B&#xe9;dirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695&#x2013;699. doi:10.1111/j.1532-5415.2005.53221.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53221.x</ArticleId><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Pergolotti M, Langer MM, Deal AM, Muss HB, Nyrop K, Williams G. Mental status evaluation in older adults with cancer: Development of the Mental Health Index-13. J Geriatr Oncol. 2019;10(2):241&#x2013;245. doi:10.1016/j.jgo.2018.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgo.2018.08.009</ArticleId><ArticleId IdType="pmc">PMC6408306</ArticleId><ArticleId IdType="pubmed">30205939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32(6):705&#x2013;714. doi:10.1016/0277-9536(91)90150-b</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0277-9536(91)90150-b</ArticleId><ArticleId IdType="pubmed">2035047</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischel LE, Ritchie C, Kober KM, et al. Age differences in fatigue, decrements in energy, and sleep disturbance in oncology patients receiving chemotherapy. Eur J Oncol Nurs. 2016;23:115&#x2013;123. doi:10.1016/j.ejon.2016.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejon.2016.07.002</ArticleId><ArticleId IdType="pmc">PMC4968953</ArticleId><ArticleId IdType="pubmed">27456383</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KA, Hicks G, Nino-Murcia G. Validity and reliability of a scale to assess fatigue. Psychiatry Res. 1991;36(3):291&#x2013;298. doi:10.1016/0165-1781(91)90027-m</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-1781(91)90027-m</ArticleId><ArticleId IdType="pubmed">2062970</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagberg LM, Jakola AS, Solheim O. Quality of life assessed with EQ-5D in patients undergoing glioma surgery: what is the responsiveness and minimal clinically important difference? Qual Life Res. 2014;23(5):1427&#x2013;1434. doi:10.1007/s11136-013-0593-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-013-0593-4</ArticleId><ArticleId IdType="pubmed">24318084</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng L, Chow E, Zhang L, et al. An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases. Support Care Cancer. 2012;20(12):3307&#x2013;3313. doi:10.1007/s00520-012-1484-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-012-1484-x</ArticleId><ArticleId IdType="pubmed">22562607</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulaziz K, Perry JJ, Taljaard M, et al. National Survey of Geriatricians to Define Functional Decline in Elderly People with Minor Trauma. Can Geriatr J. 2016;19(1):2&#x2013;8. doi:10.5770/cgj.19.192</Citation><ArticleIdList><ArticleId IdType="doi">10.5770/cgj.19.192</ArticleId><ArticleId IdType="pmc">PMC4815935</ArticleId><ArticleId IdType="pubmed">27076859</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurria A, Soto-Perez-de-Celis E, Allred JB, et al. Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. J Am Geriatr Soc. 2019;67(5):920&#x2013;927. doi:10.1111/jgs.15493</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.15493</ArticleId><ArticleId IdType="pmc">PMC6391210</ArticleId><ArticleId IdType="pubmed">30146695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy RE, Sawyer P, Williams CP, et al. Life-Space Mobility Change Predicts 6-Month Mortality. J Am Geriatr Soc. 2017;65(4):833&#x2013;838. doi:10.1111/jgs.14738</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.14738</ArticleId><ArticleId IdType="pmc">PMC5826722</ArticleId><ArticleId IdType="pubmed">28152168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy RE, Almutairi M, Williams CP, Sawyer P, Allman RM, Brown CJ. Determination of the Minimal Important Change in the Life-Space Assessment. J Am Geriatr Soc. 2019;67(3):565&#x2013;569. doi:10.1111/jgs.15707</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.15707</ArticleId><ArticleId IdType="pubmed">30536982</ArticleId></ArticleIdList></Reference><Reference><Citation>StataCorp. Published online 2021.</Citation></Reference><Reference><Citation>Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15(3):398&#x2013;405. doi:10.1111/nhs.12048</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nhs.12048</ArticleId><ArticleId IdType="pubmed">23480423</ArticleId></ArticleIdList></Reference><Reference><Citation>Portegijs E, Rantakokko M, Viljanen A, Sipil&#xe4; S, Rantanen T. Identification of Older People at Risk of ADL Disability Using the Life-Space Assessment: A Longitudinal Cohort Study. J Am Med Dir Assoc. 2016;17(5):410&#x2013;414. doi:10.1016/j.jamda.2015.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2015.12.010</ArticleId><ArticleId IdType="pubmed">26805752</ArticleId></ArticleIdList></Reference><Reference><Citation>al Snih S, Peek KM, Sawyer P, Markides KS, Allman RM, Ottenbacher KJ. Life-space mobility in Mexican Americans aged 75 and older. J Am Geriatr Soc. 2012;60(3):532&#x2013;537. doi:10.1111/j.1532-5415.2011.03822.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2011.03822.x</ArticleId><ArticleId IdType="pmc">PMC3996837</ArticleId><ArticleId IdType="pubmed">22283683</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JK, Buchan IE, van der Veer SN. Assessing life-space mobility for a more holistic view on wellbeing in geriatric research and clinical practice. Aging Clinical and Experimental Research. 2019;31(4):439&#x2013;445. doi:10.1007/S40520-018-0999-5/TABLES/2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S40520-018-0999-5/TABLES/2</ArticleId><ArticleId IdType="pmc">PMC6439151</ArticleId><ArticleId IdType="pubmed">30078096</ArticleId></ArticleIdList></Reference><Reference><Citation>Webber SC, Porter MM, Menec VH. Mobility in Older Adults: A Comprehensive Framework. Gerontologist. 2010;50(4):443&#x2013;450. doi:10.1093/GERONT/GNQ013</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/GERONT/GNQ013</ArticleId><ArticleId IdType="pubmed">20145017</ArticleId></ArticleIdList></Reference><Reference><Citation>Nightingale G, Battisti NML, Loh KP, et al. Perspectives on functional status in older adults with cancer: An interprofessional report from the International Society of Geriatric Oncology (SIOG) nursing and allied health interest group and young SIOG. Journal of Geriatric Oncology. 2021;12(4):658&#x2013;665. doi:10.1016/j.jgo.2020.10.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgo.2020.10.018</ArticleId><ArticleId IdType="pmc">PMC8102651</ArticleId><ArticleId IdType="pubmed">33172805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamaker M, Lund C, te Molder M, et al. Geriatric assessment in the management of older patients with cancer - A systematic review (update). J Geriatr Oncol. Published online May 8, 2022. doi:10.1016/j.jgo.2022.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgo.2022.04.008</ArticleId><ArticleId IdType="pubmed">35545495</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips JL, Lam L, Luckett T, Agar M, Currow D. Is the Life Space Assessment applicable to a palliative care population? Its relationship to measures of performance and quality of life. J Pain Symptom Manage. 2014;47(6):1121&#x2013;1127. doi:10.1016/j.jpainsymman.2013.06.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2013.06.017</ArticleId><ArticleId IdType="pubmed">24094702</ArticleId></ArticleIdList></Reference><Reference><Citation>Viret O, Schwarz J, Senn N, Mueller Y. Discussing age-related functional decline in family medicine: a qualitative study that explores both patient and physician perceptions. Age and Ageing. 2020;49(2):292&#x2013;299. doi:10.1093/AGEING/AFZ158</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/AGEING/AFZ158</ArticleId></ArticleIdList></Reference><Reference><Citation>Brehaut JC, O&#x2019;Connor AM, Wood TJ, et al. Validation of a decision regret scale. Med Decis Making. 2003;23(4):281&#x2013;292. doi:10.1177/0272989X03256005</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X03256005</ArticleId><ArticleId IdType="pubmed">12926578</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanarajasingam G, Basch E, Mead-Harvey C, et al. An Exploratory Analysis of the &#x201c;Was It Worth It?&#x201d; Questionnaire as a Novel Metric to Capture Patient Perceptions of Cancer Treatment. Value in Health. 2022;25(7):1081&#x2013;1086. doi:10.1016/j.jval.2021.11.1368</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2021.11.1368</ArticleId><ArticleId IdType="pmc">PMC9250647</ArticleId><ArticleId IdType="pubmed">35779938</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34611887</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-5415</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study.</ArticleTitle><Pagination><StartPage>136</StartPage><EndPage>149</EndPage><MedlinePgn>136-149</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jgs.17474</ELocationID><Abstract><AbstractText Label="BACKGROUND">Maintenance of function during cancer treatment is important to older adults. Characteristics associated with pretreatment life-space mobility and changes during non-small cell lung cancer (NSCLC) treatment remain unknown.</AbstractText><AbstractText Label="METHODS">This mixed methods cohort study recruited adults age &#x2265;65 with advanced NSCLC starting palliative chemotherapy, immunotherapy, and/or targeted therapy from a Comprehensive Cancer Center, Veterans Affairs, and safety-net clinic. Patients completed geriatric assessments including Life-Space Assessment (LSA) pretreatment and at 1, 2, 4, and 6&#x2009;months after treatment initiation. LSA scores range from 0 to 120 (greater mobility); LSA &lt;60 is considered restricted. We used mixed-effects models to examine pretreatment LSA, change from 0 to 1&#xa0;month, and change from 1 to 6&#xa0;months. A subgroup participated in semistructured interviews pretreatment and at 2 and 6&#x2009;months to understand the patient experience of life-space change. For each interview participant, we created joint displays of longitudinal LSA scores juxtaposed with illustrative quotes.</AbstractText><AbstractText Label="RESULTS">Among 93 patients, median age was 73 (range 65-94). Mean pretreatment LSA score was 67.1. On average, LSA declined 10.1 points from pretreatment to 1&#x2009;month and remained stable at 6&#x2009;months. Pretreatment LSA score was associated with several demographic, clinical, geriatric assessment, and symptom characteristics. LSA decline at 1&#x2009;month was greater among patients with high anxiety (slope&#xa0;=&#xa0;-12.6 vs. -2.3, p&#xa0;=&#xa0;0.048). Pretreatment body mass index &lt;21&#x2009;kg/m<sup>2</sup> was associated with LSA improvement from 1 to 6&#xa0;months (slope&#xa0;=&#xa0;4.1 vs. -0.04, p&#xa0;=&#xa0;0.003). Joint displays illustrated the impact of different life-space trajectories on patients' lives in their words.</AbstractText><AbstractText Label="CONCLUSION">Older adults with NSCLC have low pretreatment life space with many developing restricted life space during treatment. Incorporating life-space assessments into clinical cancer care may help older adults concretely visualize how treatment might impact their daily function to allow for informed decision making and identify early changes in mobility to implement supportive interventions.</AbstractText><CopyrightInformation>&#xa9; 2021 The American Geriatrics Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Melisa L</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0001-6390-6959</Identifier><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Alexander K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miaskowski</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departments of Physiological Nursing and Anesthesiology and Perioperative Care, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boscardin</LastName><ForeName>W John</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Harvey Jay</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Center for the Study of Aging &amp; Human Development and Duke Cancer Institute, Duke University, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Vivian</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazor</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metzger</LastName><ForeName>Lia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>New York Medical College, Valhalla, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Presley</LastName><ForeName>Carolyn J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-2607-5639</Identifier><AffiliationInfo><Affiliation>Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Grant R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Divisions of Hematology/Oncology &amp; Gerontology, Geriatrics, and Palliative Care, The University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loh</LastName><ForeName>Kah Poh</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>James P. Wilmot Cancer Institute, Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ursem</LastName><ForeName>Carling J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hematology-Oncology, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedlander</LastName><ForeName>Terence W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hematology-Oncology, Zuckerberg San Francisco General, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blakely</LastName><ForeName>Collin M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gubens</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shumay</LastName><ForeName>Dianne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Louise C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KL2 TR001870</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K76 AG064431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG056439</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03AG056439</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32CA225617</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG064374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30CA196521</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA225617</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 CA237744</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2TR001870</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30CA016058</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03AG064374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24AG068312</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA196521</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG044281</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 CA234225</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG068312</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG044281</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08CA234225</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99CA237744</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K76AG064431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA016058</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="Y">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="Y">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051346" MajorTopicYN="N">Mobility Limitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer treatment</Keyword><Keyword MajorTopicYN="N">geriatric oncology</Keyword><Keyword MajorTopicYN="N">life-space mobility</Keyword><Keyword MajorTopicYN="N">lung cancer</Keyword><Keyword MajorTopicYN="N">mixed methods</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>6</Day><Hour>7</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34611887</ArticleId><ArticleId IdType="mid">NIHMS1739893</ArticleId><ArticleId IdType="pmc">PMC8742783</ArticleId><ArticleId IdType="doi">10.1111/jgs.17474</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2018, National Cancer Institute. Bethesda, MD.</Citation></Reference><Reference><Citation>Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71: 209&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ML, Paul SM, Cooper BA, et al. Predictors of the multidimensional symptom experience of lung cancer patients receiving chemotherapy. Support Care Cancer. 2017;25: 1931&#x2013;1939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5433346</ArticleId><ArticleId IdType="pubmed">28160076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ML, Cooper BA, Paul SM, et al. Differences in Symptom Clusters Identified Using Ratings of Symptom Occurrence vs. Severity in Lung Cancer Patients Receiving Chemotherapy. J Pain Symptom Manage. 2017;54: 194&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5557657</ArticleId><ArticleId IdType="pubmed">28533161</ArticleId></ArticleIdList></Reference><Reference><Citation>Presley CJ, Arrato NA, Janse S, et al. Functional disability among older vs. younger adults with advanced non-small cell lung cancer. JCO Oncol Pract. 2021: (In press).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8258136</ArticleId><ArticleId IdType="pubmed">33939536</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried TR, Bradley EH, Towle VR, Allore H. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346: 1061&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932474</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh KP, Lam V, Webber K, et al. Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults. Journal of the National Comprehensive Cancer Network : JNCCN. 2021: 1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8517039</ArticleId><ArticleId IdType="pubmed">33857918</ArticleId></ArticleIdList></Reference><Reference><Citation>Peel C, Sawyer Baker P, Roth DL, Brown CJ, Brodner EV, Allman RM. Assessing mobility in older adults: the UAB Study of Aging Life-Space Assessment. Phys Ther. 2005;85: 1008&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pubmed">16180950</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J, Rodriguez MA, Al Snih S. Life-Space Mobility in the Elderly: Current Perspectives. Clinical interventions in aging. 2020;15: 1665&#x2013;1674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7501960</ArticleId><ArticleId IdType="pubmed">32982200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy RE, Sawyer P, Williams CP, et al. Life-Space Mobility Change Predicts 6-Month Mortality. J Am Geriatr Soc. 2017;65: 833&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5826722</ArticleId><ArticleId IdType="pubmed">28152168</ArticleId></ArticleIdList></Reference><Reference><Citation>Rantakokko M, Portegijs E, Viljanen A, Iwarsson S, Rantanen T. Life-space mobility and quality of life in community-dwelling older people. J Am Geriatr Soc. 2013;61: 1830&#x2013;1832.</Citation><ArticleIdList><ArticleId IdType="pubmed">24117303</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatt&#xe1;s-Vernaglia IF, Ramos PT, Perini MLL, et al. Impact of the COVID-19 pandemic on the life-space mobility of older adults with cancer. Journal of geriatric oncology. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883734</ArticleId><ArticleId IdType="pubmed">33640305</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart CM, Wheeler TL 2nd, Markland AD, Straughn JM Jr., Richter HE. Life-space assessment in urogynecology and gynecological oncology surgery patients: a measure of perioperative mobility and function. J Am Geriatr Soc. 2009;57: 2263&#x2013;2268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3252022</ArticleId><ArticleId IdType="pubmed">19874406</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee J, Davis GM, Beith JM, et al. Physical activity and fitness in women with metastatic breast cancer. Journal of cancer survivorship : research and practice. 2014;8: 647&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">24986228</ArticleId></ArticleIdList></Reference><Reference><Citation>American Joint Commitee on Cancer. AJCC Cancer Staging Manual. 8th edn: Springer International Publishing, 2017.</Citation></Reference><Reference><Citation>Loyd C, Beasley TM, Miltner RS, Clark D, King B, Brown CJ. Trajectories of Community Mobility Recovery After Hospitalization in Older Adults. J Am Geriatr Soc. 2018;66: 1399&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097884</ArticleId><ArticleId IdType="pubmed">29719058</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheppard KD, Sawyer P, Ritchie CS, Allman RM, Brown CJ. Life-space mobility predicts nursing home admission over 6 years. J Aging Health. 2013;25: 907&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4071297</ArticleId><ArticleId IdType="pubmed">23965310</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy RE, Almutairi M, Williams CP, Sawyer P, Allman RM, Brown CJ. Determination of the Minimal Important Change in the Life-Space Assessment. J Am Geriatr Soc. 2019;67: 565&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">30536982</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011;29: 1290&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083997</ArticleId><ArticleId IdType="pubmed">21357782</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnofsky D Performance scale. New York: Plenum Press, 1977.</Citation></Reference><Reference><Citation>Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: A standardized measure of biological and psycosocial function. JAMA. 1963;185: 914&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">14044222</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol. 1981;36: 428&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">7252074</ArticleId></ArticleIdList></Reference><Reference><Citation>Podsiadlo D, Richardson S. The timed &#x201c;Up &amp; Go&#x201d;: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39: 142&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">1991946</ArticleId></ArticleIdList></Reference><Reference><Citation>Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49: M85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">8126356</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53: 695&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohile SG, Epstein RM, Hurria A, et al. Communication With Older Patients With Cancer Using Geriatric Assessment: A Cluster-Randomized Clinical Trial From the National Cancer Institute Community Oncology Research Program. JAMA Oncol. 2019: 1&#x2013;9.</Citation></Reference><Reference><Citation>Pergolotti M, Langer MM, Deal AM, Muss HB, Nyrop K, Williams G. Mental status evaluation in older adults with cancer: Development of the Mental Health Index-13. Journal of geriatric oncology. 2019;10: 241&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6408306</ArticleId><ArticleId IdType="pubmed">30205939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32: 705&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">2035047</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischel LE, Ritchie C, Kober KM, et al. Age differences in fatigue, decrements in energy, and sleep disturbance in oncology patients receiving chemotherapy. Eur J Oncol Nurs. 2016;23: 115&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968953</ArticleId><ArticleId IdType="pubmed">27456383</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KA, Hicks G, Nino-Murcia G. Validity and reliability of a scale to assess fatigue. Psychiatry research. 1991;36: 291&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062970</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaronson NK, Ahmedzai S, Bergman B. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute. 1993;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">8433390</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera GA, Wakelee H. Lung Cancer in Never Smokers. Advances in experimental medicine and biology. 2016;893: 43&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">26667338</ArticleId></ArticleIdList></Reference><Reference><Citation>Strulov Shachar S, Williams GR. The Obesity Paradox in Cancer-Moving Beyond BMI. Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2017;26: 13&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5830139</ArticleId><ArticleId IdType="pubmed">28069727</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study. Nursing &amp; Health Sciences. 2013;15: 398&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">23480423</ArticleId></ArticleIdList></Reference><Reference><Citation>Creswell J A concise introduction to mixed methods research. Los Angeles, CA: SAGE Publications, Inc, 2015.</Citation></Reference><Reference><Citation>Phillips J, Dal Grande E, Ritchie C, Abemethy AP, Currow DC. A Population-Based Cross-Sectional Study That Defined Normative Population Data for the Life-Space Mobility Assessment-Composite Score. Journal of Pain and Symptom Management. 2015;49: 885&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">25546285</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown Johnson CG, Brodsky JL, Cataldo JK. Lung cancer stigma, anxiety, depression, and quality of life. Journal of psychosocial oncology. 2014;32: 59&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4634635</ArticleId><ArticleId IdType="pubmed">24428251</ArticleId></ArticleIdList></Reference><Reference><Citation>Auais M, Alvarado B, Guerra R, et al. Fear of falling and its association with life-space mobility of older adults: a cross-sectional analysis using data from five international sites. Age Ageing. 2017;46: 459&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5405754</ArticleId><ArticleId IdType="pubmed">28043980</ArticleId></ArticleIdList></Reference><Reference><Citation>Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non&#x2013;Small-Cell Lung Cancer. New England Journal of Medicine. 2018;378: 113&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">29151359</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378: 2078&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pubmed">29658856</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevino KM, Saracino RM, Roth AJ. Symptomatology, assessment, and treatment of anxiety in older adults with cancer. Journal of geriatric oncology. 2021;12: 316&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7303031</ArticleId><ArticleId IdType="pubmed">32565145</ArticleId></ArticleIdList></Reference><Reference><Citation>Vellas B, Villars H, Abellan G, et al. Overview of the MNA--Its history and challenges. J Nutr Health Aging. 2006;10: 456&#x2013;463; discussion 463-455.</Citation><ArticleIdList><ArticleId IdType="pubmed">17183418</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepshelovich D, Xu W, Lu L, et al. Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. J Thorac Oncol. 2019;14: 1594&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6734935</ArticleId><ArticleId IdType="pubmed">31163278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie CS, Locher JL, Roth DL, McVie T, Sawyer P, Allman R. Unintentional weight loss predicts decline in activities of daily living function and life-space mobility over 4 years among community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2008;63: 67&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">18245763</ArticleId></ArticleIdList></Reference><Reference><Citation>Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nature Reviews Endocrinology. 2018;14: 513&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6241236</ArticleId><ArticleId IdType="pubmed">30065268</ArticleId></ArticleIdList></Reference><Reference><Citation>Correa-de-Araujo R, Addison O, Miljkovic I, et al. Myosteatosis in the Context of Skeletal Muscle Function Deficit: An Interdisciplinary Workshop at the National Institute on Aging. Frontiers in Physiology. 2020; 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7438777</ArticleId><ArticleId IdType="pubmed">32903666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol. 2011;29: 3457&#x2013;3465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624700</ArticleId><ArticleId IdType="pubmed">21810685</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynn NW, Santanasto AJ, Simonsick EM, et al. The Pittsburgh Fatigability scale for older adults: development and validation. J Am Geriatr Soc. 2015;63: 130&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4971882</ArticleId><ArticleId IdType="pubmed">25556993</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes F, Tay R, Chiramel J, Califano R. The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer. Drugs Aging. 2018;35: 819&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">30105645</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva MD, Apolinario D, Avelino-Silva TJ, et al. The Impact of Frailty on the Relationship between Life-Space Mobility and Quality of Life in Older Adults during the COVID-19 Pandemic. The journal of nutrition, health &amp; aging. 2021;25: 440&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7678592</ArticleId><ArticleId IdType="pubmed">33786560</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35123919</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-4076</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of geriatric oncology</Title><ISOAbbreviation>J Geriatr Oncol</ISOAbbreviation></Journal><ArticleTitle>"You have to be sure that the patient has the full picture": Adaptation of the Best Case/Worst Case communication tool for geriatric oncology.</ArticleTitle><Pagination><StartPage>606</StartPage><EndPage>613</EndPage><MedlinePgn>606-613</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jgo.2022.01.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1879-4068(22)00015-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Shared decision making (SDM) is especially important for older adults with cancer given the risks of over- and undertreatment, uncertainty regarding benefits/harms worsened by research underrepresentation, and individual preferences. We aimed to adapt the Best Case/Worst Case (BC/WC) communication tool, which improves SDM in geriatric surgery, to geriatric oncology.</AbstractText><AbstractText Label="METHODS">We conducted focus groups with 40 stakeholders (fourteen older adults with lung cancer, twelve caregivers, fourteen medical oncologists) to elicit perspectives on using the BC/WC tool for geriatric oncology and to identify components needing refinement. During each focus group, participants viewed a BC/WC demonstration video and answered questions modified from the Decision Aid Acceptability Scale. We analyzed transcripts using deductive and inductive thematic analyses.</AbstractText><AbstractText Label="DISCUSSION">Participants believed that the BC/WC tool could help patients understand their cancer care choices, explore tradeoffs and picture potential outcomes, and deliberate about decisions based on their goals, preferences, and values. Oncologists also reported the tool could guide conversations to address points that may frequently be skipped (e.g., alternative options, treatment goals). Participant preferences varied widely regarding discussion of the worst-case scenario and desire for statistical information.</AbstractText><AbstractText Label="CONCLUSION">The BC/WC tool is a promising strategy that may improve SDM in geriatric oncology and patient understanding of alternative options and treatment goals. Based on participant input, adaptations will include framing cancer care as a series of decisions, eliciting patient preferences and asking permission before offering the worst-case scenario, and selection of the two most relevant options to present if multiple exist.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Melisa L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA; Division of Geriatrics, University of California, San Francisco and San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA. Electronic address: melisa.wong@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicosia</LastName><ForeName>Francesca M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco and San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA; Institute for Health &amp; Aging, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Alexander K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco and San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Louise C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco and San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Vivian</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Harvey Jay</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Center for the Study of Aging &amp; Human Development and Duke Cancer Institute, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loh</LastName><ForeName>Kah Poh</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>James P Wilmot Cancer Institute, Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohile</LastName><ForeName>Supriya G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>James P Wilmot Cancer Institute, Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ursem</LastName><ForeName>Carling J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA; Division of Hematology-Oncology, San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarze</LastName><ForeName>Margaret L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Department of Medical History and Bioethics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG068312</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K76 AG064431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 CA237744</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UG1 CA189961</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33 AG059206</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG056589</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Geriatr Oncol</MedlineTA><NlmUniqueID>101534770</NlmUniqueID><ISSNLinking>1879-4068</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003142" MajorTopicYN="N">Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="N">Decision Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080536" MajorTopicYN="N">Decision Making, Shared</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008495" MajorTopicYN="N">Medical Oncology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072103" MajorTopicYN="Y">Oncologists</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Communication tool</Keyword><Keyword MajorTopicYN="N">Geriatric oncology</Keyword><Keyword MajorTopicYN="N">Lung cancer</Keyword><Keyword MajorTopicYN="N">Shared decision making</Keyword></KeywordList><CoiStatement>DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST. MLW, KPL, and MLS reported conflicts of interest outside of the submitted work (MLW: receives royalties from UpToDate, immediate family member is an employee of Genentech with stock ownership; KPL: consultant for Pfizer and Seattle Genetics, receipt of honorarium from Pfizer; MLS: immediate family member has ownership interest in MezLight LLC). The remaining authors have no conflicts to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>6</Day><Hour>20</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35123919</ArticleId><ArticleId IdType="mid">NIHMS1793143</ArticleId><ArticleId IdType="pmc">PMC9232997</ArticleId><ArticleId IdType="doi">10.1016/j.jgo.2022.01.014</ArticleId><ArticleId IdType="pii">S1879-4068(22)00015-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hack TF, Degner LF, Watson P, Sinha L. Do patients benefit from participating in medical decision making? Longitudinal follow-up of women with breast cancer. Psychooncology. 2006;15(1):9&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">15669023</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattellari M, Butow PN, Tattersall MH. Sharing decisions in cancer care. Soc Sci Med. 2001;52(12):1865&#x2013;1878.</Citation><ArticleIdList><ArticleId IdType="pubmed">11352412</ArticleId></ArticleIdList></Reference><Reference><Citation>DuMontier C, Loh KP, Soto-Perez-de-Celis E, Dale W. Decision Making in Older Adults With Cancer. Journal of Clinical Oncology. 2021;39(19):2164&#x2013;2174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260915</ArticleId><ArticleId IdType="pubmed">34043434</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaston CM, Mitchell G. Information giving and decision-making in patients with advanced cancer: a systematic review. Soc Sci Med. 2005;61(10):2252&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pubmed">15922501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehl KL, Landrum MB, Arora NK, Ganz PA, van Ryn M, Mack JW, et al. Association of Actual and Preferred Decision Roles With Patient-Reported Quality of Care: Shared Decision Making in Cancer Care. JAMA Oncol. 2015;1(1):50&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4937185</ArticleId><ArticleId IdType="pubmed">26182303</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhaya S, Hubbard-Lucey VM, Yu JX. Immuno-oncology drug development forges on despite COVID-19. Nat Rev Drug Discov. 2020;19(11):751&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">32948858</ArticleId></ArticleIdList></Reference><Reference><Citation>Melosky B, Wheatley-Price P, Juergens RA, Sacher A, Leighl NB, Tsao MS, et al. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. Lung Cancer. 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">34353680</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzocco K, Masiero M, Carriero MC, Pravettoni G. The role of emotions in cancer patients&#x2019; decision-making. Ecancermedicalscience. 2019;13:914&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6467455</ArticleId><ArticleId IdType="pubmed">31123497</ArticleId></ArticleIdList></Reference><Reference><Citation>DuMontier C, Loh KP, Bain PA, Silliman RA, Hshieh T, Abel GA, et al. Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review. Journal of Clinical Oncology.0(0):JCO.19.02809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392742</ArticleId><ArticleId IdType="pubmed">32250717</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedrak MS, Freedman RA, Cohen HJ, Muss HB, Jatoi A, Klepin HD, et al. Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. CA Cancer J Clin. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854940</ArticleId><ArticleId IdType="pubmed">33002206</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson DR, Loh KP. Improving personalized treatment decision-making for older adults with cancer: The necessity of eliciting patient preferences. Journal of Geriatric Oncology. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8660947</ArticleId><ArticleId IdType="pubmed">34120848</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostoft S, van den Bos F, Pedersen R, Hamaker ME. Shared decision-making in older patients with cancer - What does the patient want? Journal of Geriatric Oncology. 2021;12(3):339&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">32839118</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried TR, Bradley EH, Towle VR, Allore H. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346(14):1061&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932474</ArticleId></ArticleIdList></Reference><Reference><Citation>Celis ESPD, Li D, Sun C-L, Kim H, Twardowski P, Fakih M, et al. Patient-defined goals and preferences among older adults with cancer starting chemotherapy (CT). Journal of Clinical Oncology. 2018;36(15_suppl):10009&#x2013;10009.</Citation></Reference><Reference><Citation>Loh KP, Mohile SG, Epstein RM, McHugh C, Flannery M, Culakova E, et al. Willingness to bear adversity and beliefs about the curability of advanced cancer in older adults. Cancer. 2019;125(14):2506&#x2013;2513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602839</ArticleId><ArticleId IdType="pubmed">30920646</ArticleId></ArticleIdList></Reference><Reference><Citation>National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Older Adult Oncology. Version 1.2021; https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf.
Accessed 29 July 2021.</Citation></Reference><Reference><Citation>Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326&#x2013;2347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6063790</ArticleId><ArticleId IdType="pubmed">29782209</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh KP, Soto P&#xe9;rez de Celis E, Duberstein PR, Culakova E, Epstein RM, Xu H, et al. Patient and caregiver agreement on prognosis estimates for older adults with advanced cancer. Cancer. 2020;127(1):149&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736110</ArticleId><ArticleId IdType="pubmed">33036063</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh KP, Mohile SG, Lund JL, Epstein R, Lei L, Culakova E, et al. Beliefs About Advanced Cancer Curability in Older Patients, Their Caregivers, and Oncologists. Oncologist. 2019;24(6):e292&#x2013;e302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6656513</ArticleId><ArticleId IdType="pubmed">31015317</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson LL, Temel B, Fuh CX, Server C, Kay P, Landay S, et al. Perceptions of medical status and treatment goal among older adults with advanced cancer. J Geriatr Oncol. 2020;11(6):937&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pubmed">31813839</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Jawahri A, Nelson-Lowe M, VanDusen H, Traeger L, Abel GA, Greer JA, et al. Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist. 2019;24(2):247&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6369944</ArticleId><ArticleId IdType="pubmed">30139841</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh KP, Xu H, Back A, Duberstein PR, Gupta Mohile S, Epstein R, et al. Patient-hematologist discordance in perceived chance of cure in hematologic malignancies: A multicenter study. Cancer. 2020;126(6):1306&#x2013;1314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7050385</ArticleId><ArticleId IdType="pubmed">31809566</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh KP, Abdallah M, Kadambi S, Wells M, Kumar AJ, Mendler JH, et al. Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists. Leuk Lymphoma. 2021;62(2):387&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7878016</ArticleId><ArticleId IdType="pubmed">33040623</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattellari M, Voigt KJ, Butow PN, Tattersall MH. When the treatment goal is not cure: are cancer patients equipped to make informed decisions? J Clin Oncol. 2002;20(2):503&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">11786580</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, et al. Patients&#x2019; expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367(17):1616&#x2013;1625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613151</ArticleId><ArticleId IdType="pubmed">23094723</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeks JC, Cook EF, O&#x2019;Day SJ, Peterson LM, Wenger N, Reding D, et al. Relationship between cancer patients&#x2019; predictions of prognosis and their treatment preferences. Jama. 1998;279(21):1709&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pubmed">9624023</ArticleId></ArticleIdList></Reference><Reference><Citation>Temel JS, Greer JA, Admane S, Gallagher ER, Jackson VA, Lynch TJ, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol. 2011;29(17):2319&#x2013;2326.</Citation><ArticleIdList><ArticleId IdType="pubmed">21555700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruser JM, Nabozny MJ, Steffens NM, Brasel KJ, Campbell TC, Gaines ME, et al. &#x201c;Best Case/Worst Case&#x201d;: Qualitative Evaluation of a Novel Communication Tool for Difficult in-the-Moment Surgical Decisions. J Am Geriatr Soc. 2015;63(9):1805&#x2013;1811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4747100</ArticleId><ArticleId IdType="pubmed">26280462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruser JM, Taylor LJ, Campbell TC, Zelenski A, Johnson SK, Nabozny MJ, et al. &#x201c;Best Case/Worst Case&#x201d;: Training Surgeons to Use a Novel Communication Tool for High-Risk Acute Surgical Problems. J Pain Symptom Manage. 2017;53(4):711&#x2013;719 e715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5374034</ArticleId><ArticleId IdType="pubmed">28062349</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor LJ, Nabozny MJ, Steffens NM, Tucholka JL, Brasel KJ, Johnson SK, et al. A Framework to Improve Surgeon Communication in High-Stakes Surgical Decisions: Best Case/Worst Case. JAMA Surg. 2017;152(6):531&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479749</ArticleId><ArticleId IdType="pubmed">28146230</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann CJ, Zelenski AB, Buffington A, Baggett ND, Tucholka JL, Weis HB, et al. Best Case/Worst Case for the Trauma ICU: Development and Pilot Testing of a Communication Tool for Older Adults with Traumatic Injury. J Trauma Acute Care Surg. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8939782</ArticleId><ArticleId IdType="pubmed">34039930</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann CJ, Jhagroo RA, Wakeen M, Schueller K, Zelenski A, Tucholka JL, et al. Opportunities to Improve Shared Decision Making in Dialysis Decisions for Older Adults with Life-Limiting Kidney Disease: A Pilot Study. J Palliat Med. 2020;23(5):627&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7232635</ArticleId><ArticleId IdType="pubmed">31930929</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarze ML, Zelenski A, Baggett ND, Kalbfell E, Ljumani F, Silverman E, et al. Best Case/Worst Case: ICU (COVID-19)-A Tool to Communicate with Families of Critically Ill Patients with COVID-19. Palliat Med Rep. 2020;1(1):3&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7446244</ArticleId><ArticleId IdType="pubmed">32856022</ArticleId></ArticleIdList></Reference><Reference><Citation>Elwyn G, Durand MA, Song J, Aarts J, Barr PJ, Berger Z, et al. A three-talk model for shared decision making: multistage consultation process. BMJ. 2017;359:j4891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5683042</ArticleId><ArticleId IdType="pubmed">29109079</ArticleId></ArticleIdList></Reference><Reference><Citation>Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3445676</ArticleId><ArticleId IdType="pubmed">22618581</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarze ML, Taylor LJ. Managing Uncertainty - Harnessing the Power of Scenario Planning. N Engl J Med. 2017;377(3):206&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8369433</ArticleId><ArticleId IdType="pubmed">28723329</ArticleId></ArticleIdList></Reference><Reference><Citation>Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al.
SEER Cancer Statistics Review, 1975&#x2013;2018, National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/csr/1975_2018/, based on November 2020 SEER data submission, posted to the SEER web site, April
2021.</Citation></Reference><Reference><Citation>Loh KP, Lam V, Webber K, Padam S, Sedrak MS, Musinipally V, et al. Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults. J Natl Compr Canc Netw. 2021;19(9):1055&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8517039</ArticleId><ArticleId IdType="pubmed">33857918</ArticleId></ArticleIdList></Reference><Reference><Citation>Presley CJ, Arrato NA, Janse S, Shields PG, Carbone DP, Wong ML, et al. Functional disability among older vs. younger adults with advanced non-small cell lung cancer. JCO Oncol Pract. 2021:(In press).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8258136</ArticleId><ArticleId IdType="pubmed">33939536</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ML, Paul SM, Cooper BA, Dunn LB, Hammer MJ, Conley YP, et al. Predictors of the multidimensional symptom experience of lung cancer patients receiving chemotherapy. Support Care Cancer. 2017;25(6):1931&#x2013;1939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5433346</ArticleId><ArticleId IdType="pubmed">28160076</ArticleId></ArticleIdList></Reference><Reference><Citation>Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research. Adm Policy Ment Health. 2015;42(5):533&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4012002</ArticleId><ArticleId IdType="pubmed">24193818</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor A, Cranney A. User Manual - Acceptability [document on the Internet]. 1996. 
[modified 2002]; http://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Acceptability.pdf.
Accessed June 6, 2018.</Citation></Reference><Reference><Citation>Fereday J, Muir-Cochrane E. Demonstrating Rigor Using Thematic Analysis: A Hybrid Approach of Inductive and Deductive Coding and Theme Development. International Journal of Qualitative Methods. 2006;5(1):80&#x2013;92.</Citation></Reference><Reference><Citation>Braun V, Clarke V. To saturate or not to saturate? Questioning data saturation as a useful concept for thematic analysis and sample-size rationales. Qualitative Research in Sport, Exercise and Health. 2021;13(2):201&#x2013;216.</Citation></Reference><Reference><Citation>Robinson TM, Alexander SC, Hays M, Jeffreys AS, Olsen MK, Rodriguez KL, et al. Patient&#x2013;oncologist communication in advanced cancer: predictors of patient perception of prognosis. Supportive Care in Cancer. 2008;16(9):1049&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864029</ArticleId><ArticleId IdType="pubmed">18196288</ArticleId></ArticleIdList></Reference><Reference><Citation>Donelle L, Arocha JF, Hoffman-Goetz L. Health literacy and numeracy: key factors in cancer risk comprehension. Chronic Dis Can. 2008;29(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19036218</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegwarth O, Gigerenzer G. The Barrier to Informed Choice in Cancer Screening: Statistical Illiteracy in Physicians and Patients. Recent Results Cancer Res. 2018;210:207&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">28924688</ArticleId></ArticleIdList></Reference><Reference><Citation>Davids SL, Schapira MM, McAuliffe TL, Nattinger AB. Predictors of pessimistic breast cancer risk perceptions in a primary care population. J Gen Intern Med. 2004;19(4):310&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1492192</ArticleId><ArticleId IdType="pubmed">15061739</ArticleId></ArticleIdList></Reference><Reference><Citation>McCleary NJ, Cleveland J, Zhang S, Lepisto EM, Lee S, Hassett MJ, et al. Patient-reported health literacy and numeracy among new patients seeking consultation at a comprehensive cancer center. Journal of Clinical Oncology. 2020;38(15_suppl):7038&#x2013;7038.</Citation></Reference><Reference><Citation>Amalraj S, Starkweather C, Nguyen C, Naeim A. Health literacy, communication, and treatment decision-making in older cancer patients. Oncology (Williston Park). 2009;23(4):369&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">19476267</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32951293</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-490X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The oncologist</Title><ISOAbbreviation>Oncologist</ISOAbbreviation></Journal><ArticleTitle>Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729).</ArticleTitle><Pagination><StartPage>e435</StartPage><EndPage>e444</EndPage><MedlinePgn>e435-e444</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/onco.13527</ELocationID><Abstract><AbstractText Label="BACKGROUND">Prior comparisons of chemotherapy adverse events (AEs) by age and performance status (PS) are limited by the traditional maximum grade approach, which ignores low-grade AEs and longitudinal changes.</AbstractText><AbstractText Label="MATERIALS AND METHODS">To compare fatigue and neuropathy longitudinally by age (&lt;65, &#x2265;65 years) and PS (0-1, 2), we analyzed data from a large phase III trial of carboplatin and paclitaxel versus paclitaxel for advanced non-small cell lung cancer (CALGB 9730, n =&#x2009;529). We performed multivariable (a) linear mixed models to estimate mean AE grade over time, (b) linear regression to estimate area under the curve (AUC), and (c) proportional hazards models to estimate the hazard ratio of developing grade &#x2265;2 AE, as well as traditional maximum grade analyses.</AbstractText><AbstractText Label="RESULTS">Older patients had on average a 0.17-point (95% confidence interval [CI], 0.00-0.34; p = .049) higher mean fatigue grade longitudinally compared with younger patients. PS 2 was associated with earlier development of grade &#x2265;2 fatigue (hazard ratio [HR], 1.56; 95% CI, 1.07-2.27; p = .02). For neuropathy, older age was associated with earlier development of grade &#x2265;2 neuropathy (HR, 1.41; 95% CI, 1.00-1.97; p = .049). Patients with PS 2 had a 1.30 point lower neuropathy AUC (95% CI, -2.36 to -0.25; p = .02) compared with PS 0-1. In contrast, maximum grade analyses only detected a higher percentage of older adults with grade &#x2265;3 fatigue and neuropathy at some point during treatment.</AbstractText><AbstractText Label="CONCLUSION">Our comparison of complementary but distinct aspects of chemotherapy toxicity identified important longitudinal differences in fatigue and neuropathy by age and PS that are missed by the traditional maximum grade approach. Clinical trial identification number: NCT00003117 (CALGB 9730) IMPLICATIONS FOR PRACTICE: The traditional maximum grade approach ignores persistent low-grade adverse events (AEs) and changes over time. This toxicity over time analysis of fatigue and neuropathy during chemotherapy for advanced non-small cell lung cancer demonstrates how to use longitudinal methods to comprehensively characterize AEs over time by age and performance status (PS). We identified important longitudinal differences in fatigue and neuropathy that are missed by the maximum grade approach. This new information about how older adults and patients with PS 2 experience these toxicities longitudinally may be used clinically to improve discussions about treatment options and what to expect to inform shared decision making and symptom management.</AbstractText><CopyrightInformation>&#xa9; AlphaMed Press 2020.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Melisa L</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0001-6390-6959</Identifier><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Junheng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Alliance Statistics and Data Center, Duke University, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thanarajasingam</LastName><ForeName>Gita</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Hematology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sloan</LastName><ForeName>Jeff A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dueck</LastName><ForeName>Amylou C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Alliance Statistics and Data Center, Mayo Clinic, Scottsdale, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novotny</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Jatoi</LastName><ForeName>Aminah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurria</LastName><ForeName>Arti</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Louise C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of California, San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miaskowski</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physiological Nursing, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Harvey J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Center for the Study of Aging and Human Development, Duke University, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>William A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Lineberger Comprehensive Cancer Center, Division of Hematology/Oncology, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feliciano</LastName><ForeName>Josephine L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Center, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stinchcombe</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Duke Cancer Institute, Duke University, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaofei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Alliance Statistics and Data Center, Duke University, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KL2 TR001870</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K76 AG064431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR002379</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG056439</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U10 CA180802</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UG1 CA232760</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UG1 CA233373</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UG1 CA189823</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UG1 CA233196</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA033572</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U10 CA180838</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG044281</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oncologist</MedlineTA><NlmUniqueID>9607837</NlmUniqueID><ISSNLinking>1083-7159</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>BG3F62OND5</RegistryNumber><NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016190" MajorTopicYN="N">Carboplatin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemotherapy</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Geriatric oncology</Keyword><Keyword MajorTopicYN="N">Lung cancer</Keyword><Keyword MajorTopicYN="N">Neuropathy</Keyword></KeywordList><CoiStatement>
<i>Disclosures of potential conflicts of interest may be found at the end of this article</i>.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>20</Day><Hour>20</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32951293</ArticleId><ArticleId IdType="pmc">PMC7930405</ArticleId><ArticleId IdType="doi">10.1002/onco.13527</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Smith BD, Smith GL, Hurria A et al. Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758&#x2013;2765.</Citation><ArticleIdList><ArticleId IdType="pubmed">19403886</ArticleId></ArticleIdList></Reference><Reference><Citation>
Basch E, Campbell A, Hudgens S et al. Broadening the definition of tolerability in cancer clinical trials to better measure the patient experience. 2018. Friends of Cancer Research. Available at https://www.focr.org/sites/default/files/pdf/Comparative%20Tolerability%20Whitepaper_FINAL.pdf. Accessed March 6, 2020.</Citation></Reference><Reference><Citation>Given CW, Given B, Azzouz F et al. Comparison of changes in physical functioning of elderly patients with new diagnoses of cancer. Med Care 2000;38:482&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">10800975</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajra A, Zemla TJ, Jatoi A et al. Time&#x2010;to&#x2010;treatment&#x2010;failure and related outcomes among 1000+ advanced non&#x2010;small cell lung cancer patients: Comparisons between older versus younger patients (Alliance A151711). J Thorac Oncol 2018;13:996&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015776</ArticleId><ArticleId IdType="pubmed">29608967</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlesi F, Mazieres J, Merlio JP et al. Routine molecular profiling of patients with advanced non&#x2010;small&#x2010;cell lung cancer: Results of a 1&#x2010;year nationwide programme of the french cooperative thoracic intergroup (IFCT). Lancet 2016;387:1415&#x2013;1426.</Citation><ArticleIdList><ArticleId IdType="pubmed">26777916</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok TSKWu Y&#x2010;LKudaba I et al. Pembrolizumab versus chemotherapy for previously untreated, PD&#x2010;L1&#x2010;expressing, locally advanced or metastatic non&#x2010;small&#x2010;cell lung cancer (KEYNOTE&#x2010;042): A randomised, open&#x2010;label, controlled, phase 3 trial. Lancet 2019;393:1819&#x2013;1830.</Citation><ArticleIdList><ArticleId IdType="pubmed">30955977</ArticleId></ArticleIdList></Reference><Reference><Citation>Paz&#x2010;Ares L, Luft A, Vicente D et al. Pembrolizumab plus chemotherapy for squamous non&#x2010;small&#x2010;cell lung cancer. N Engl J Med 2018;379:2040&#x2013;2051.</Citation><ArticleIdList><ArticleId IdType="pubmed">30280635</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensing TA, Peterman AH, Schell MJ et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003;98:779&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">12910523</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallis AG, Karampeazis A, Vamvakas L et al. Efficacy and treatment tolerance in older patients with NSCLC: A meta&#x2010;analysis of five phase III randomized trials conducted by the hellenic oncology research group. Ann Oncol 2011;22:2448&#x2013;2455.</Citation><ArticleIdList><ArticleId IdType="pubmed">21393380</ArticleId></ArticleIdList></Reference><Reference><Citation>Lilenbaum RC, Herndon JE 2nd, List MA et al. Single&#x2010;agent versus combination chemotherapy in advanced non&#x2010;small&#x2010;cell lung cancer: The cancer and leukemia group B (study 9730). J Clin Oncol 2005;23:190&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">15625373</ArticleId></ArticleIdList></Reference><Reference><Citation>Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly. The experience of the eastern cooperative oncology group. Cancer 1983;52:1986&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">6354419</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovanazzi&#x2010;Bannon S, Rademaker A, Lai G et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: An Illinois cancer center study. J Clin Oncol 1994;12:2447&#x2013;2452.</Citation><ArticleIdList><ArticleId IdType="pubmed">7964962</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanarajasingam G, Atherton PJ, Novotny PJ et al. Longitudinal adverse event assessment in oncology clinical trials: The toxicity over time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Lancet Oncol 2016;17:663&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910515</ArticleId><ArticleId IdType="pubmed">27083333</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanarajasingam G, Minasian LM, Baron F et al. Beyond maximum grade: Modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol 2018;5:e563&#x2013;e598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6261436</ArticleId><ArticleId IdType="pubmed">29907552</ArticleId></ArticleIdList></Reference><Reference><Citation>Luciani A, Jacobsen PB, Extermann M et al. Fatigue and functional dependence in older cancer patients. Am J Clin Oncol 2008;31:424&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">18838877</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ML, Cooper BA, Paul SM et al. Age&#x2010;related differences in patient&#x2010;reported and objective measures of chemotherapy&#x2010;induced peripheral neuropathy among cancer survivors. Support Care Cancer 2019;27:3905&#x2013;3912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697247</ArticleId><ArticleId IdType="pubmed">30770977</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ML, Paul SM, Cooper BA et al. Predictors of the multidimensional symptom experience of lung cancer patients receiving chemotherapy. Support Care Cancer 2017;25:1931&#x2013;1939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5433346</ArticleId><ArticleId IdType="pubmed">28160076</ArticleId></ArticleIdList></Reference><Reference><Citation>Mols F, Beijers T, Vreugdenhil G et al. Chemotherapy&#x2010;induced peripheral neuropathy and its association with quality of life: A systematic review. Support Care Cancer 2014;22:2261&#x2013;2269.</Citation><ArticleIdList><ArticleId IdType="pubmed">24789421</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ML, Paul SM, Mastick J et al. Characteristics associated with physical function trajectories in older adults with cancer during chemotherapy. J Pain Symptom Manage 2018;56:678&#x2013;688.e671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6195841</ArticleId><ArticleId IdType="pubmed">30144536</ArticleId></ArticleIdList></Reference><Reference><Citation>Miaskowski C, Mastick J, Paul SM et al. Chemotherapy&#x2010;induced neuropathy in cancer survivors. J Pain Symptom Manage 2017;54:204&#x2013;218.e202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496793</ArticleId><ArticleId IdType="pubmed">28063866</ArticleId></ArticleIdList></Reference><Reference><Citation>Tofthagen C, Overcash J, Kip K. Falls in persons with chemotherapy&#x2010;induced peripheral neuropathy. Support Care Cancer 2012;20:583&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5386000</ArticleId><ArticleId IdType="pubmed">21380613</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Medicines Agency
. Guideline on missing data in confirmatory clinical trials; 2010. Available at https://www.ema.europa.eu/en/documents/scientific&#x2010;guideline/guideline&#x2010;missing&#x2010;data&#x2010;confirmatory&#x2010;clinical&#x2010;trials_en.pdf. Accessed May 2, 2020.</Citation></Reference><Reference><Citation>U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry developing products for weight management; 2007. Available at https://www.fda.gov/media/71252/download. Accessed May 5, 2020.</Citation></Reference><Reference><Citation>Thanarajasingam G, Leonard JP, Witzig TE et al. Longitudinal toxicity over time (ToxT) analysis to evaluate tolerability: A case study of lenalidomide in CALGB 50401 (Alliance). Lancet Haematol 2020;7:e490&#x2013;e497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7457391</ArticleId><ArticleId IdType="pubmed">32470440</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopwood P, Stephens RJ. Depression in patients with lung cancer: Prevalence and risk factors derived from quality&#x2010;of&#x2010;life data. J Clin Oncol 2000;18:893&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">10673533</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Comprehensive Cancer Network
. Clinical practice guidelines in oncology: Cancer&#x2010;related fatigue. (Version 2.2020). Available at https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf. Accessed May 4 2020.</Citation></Reference><Reference><Citation>Hershman DL, Till C, Wright JD et al. Comorbidities and risk of chemotherapy&#x2010;induced peripheral neuropathy among participants 65&#x2009;years or older in Southwest Oncology Group clinical trials. J Clin Oncol 2016;34:3014&#x2013;3022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5012713</ArticleId><ArticleId IdType="pubmed">27325863</ArticleId></ArticleIdList></Reference><Reference><Citation>Karavasilis V, Papadimitriou C, Gogas H et al. Safety and tolerability of anthracycline&#x2010;containing adjuvant chemotherapy in elderly high&#x2010;risk breast cancer patients. Clin Breast Cancer 2016;16:291&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">26791750</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb NA, Smith AG, Singleton JR et al. The association of chemotherapy&#x2010;induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol 2016;73:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6715416</ArticleId><ArticleId IdType="pubmed">27183099</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildes TM, Maggiore RJ, Tew WP et al. Factors associated with falls in older adults with cancer: A validated model from the Cancer and Aging Research Group. Support Care Cancer 2018;26:3563&#x2013;3570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6117216</ArticleId><ArticleId IdType="pubmed">29705872</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson TM, Dueck AC, Satele DV et al. Clinician vs patient reporting of baseline and postbaseline symptoms for adverse event assessment in cancer clinical trials. JAMA Oncol 2019;6:437&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990818</ArticleId><ArticleId IdType="pubmed">31876902</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson TM, Ryan SJ, Bennett AV et al. The association between clinician&#x2010;based common terminology criteria for adverse events (CTCAE) and patient&#x2010;reported outcomes (PRO): A systematic review. Support Care Cancer 2016;24:3669&#x2013;3676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4919215</ArticleId><ArticleId IdType="pubmed">27260018</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Cancer Institute Healthcare Delivery Research Program
. Patient&#x2010;reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO&#x2010;CTCAE). Available at https://healthcaredelivery.cancer.gov/pro&#x2010;ctcae/. Accessed December 12, 2019.</Citation></Reference><Reference><Citation>Basch E, Deal AM, Kris MG et al. Symptom monitoring with patient&#x2010;reported outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol 2016;34:557&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4872028</ArticleId><ArticleId IdType="pubmed">26644527</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34043444</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-7755</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>19</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title><ISOAbbreviation>J Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>Immunotherapy in Older Adults With Cancer.</ArticleTitle><Pagination><StartPage>2115</StartPage><EndPage>2127</EndPage><MedlinePgn>2115-2127</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.21.00138</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Presley</LastName><ForeName>Carolyn J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-2607-5639</Identifier><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0922-2665</Identifier><AffiliationInfo><Affiliation>Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burd</LastName><ForeName>Christin E</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0000-0002-7919-3954</Identifier><AffiliationInfo><Affiliation>Departments of Molecular Genetics, Cancer Biology and Genetics, The Ohio State University, Columbus, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanesvaran</LastName><ForeName>Ravindran</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2351-881X</Identifier><AffiliationInfo><Affiliation>Division of Medical Oncology, National Cancer Centre Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Melisa L</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0001-6390-6959</Identifier><AffiliationInfo><Affiliation>Divisions of Hematology/Oncology and Geriatrics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG059711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K76 AG064431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG056439</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG064374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33 AG059206</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG044281</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Oncol</MedlineTA><NlmUniqueID>8309333</NlmUniqueID><ISSNLinking>0732-183X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Carolyn J. Presley</b><b>Consulting or Advisory Role:</b> PotentiaMetrics, Onc Live <b>Fabio Gomes</b><b>Honoraria:</b> AstraZeneca <b>Christin E. Burd</b><b>Stock and Other Ownership Interests:</b> Abbvie, Luminex, GE Healthcare, Gilead Sciences <b>Ravindran Kanesvaran</b><b>Honoraria:</b> Astellas Pharma, Novartis, Janssen, MSD Oncology, Bristol-Myers Squibb<b>Consulting or Advisory Role:</b> Pfizer, Astellas Pharma, Novartis, MSD Oncology, Janssen Oncology<b>Research Funding:</b> Sanofi, Janssen<b>Travel, Accommodations, Expenses:</b> Astellas Pharma, MSD Oncology, Bristol-Myers Squibb <b>Melisa L. Wong</b><b>Employment:</b> Roche/Genentech<b>Stock and Other Ownership Interests:</b> Roche/GenentechNo other potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>17</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34043444</ArticleId><ArticleId IdType="pmc">PMC8260908</ArticleId><ArticleId IdType="doi">10.1200/JCO.21.00138</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2017. Bethesda, MD: National Cancer Institute;</Citation></Reference><Reference><Citation>Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: Burdens upon an aging, changing nation J Clin Oncol 272758&#x2013;27652009</Citation><ArticleIdList><ArticleId IdType="pubmed">19403886</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmer JR, Rodriguez-Abreu D, Robinson AG, et al. KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) 50% Ann Oncol 31S1181&#x2013;S11822020</Citation></Reference><Reference><Citation>Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma N Engl J Med 3771345&#x2013;13562017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5706778</ArticleId><ArticleId IdType="pubmed">28889792</ArticleId></ArticleIdList></Reference><Reference><Citation>Gettinger S, Borghaei H, Brahmer J, et al. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: Nivolumab vs docetaxel in previously treated NSCLC J Thorac Oncol 14S244&#x2013;S2452019</Citation></Reference><Reference><Citation>Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363711&#x2013;7232010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549297</ArticleId><ArticleId IdType="pubmed">20525992</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25:3753.</Citation><ArticleIdList><ArticleId IdType="pubmed">30787022</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedrak MS, Freedman RA, Cohen HJ, et al. Older adult participation in cancer clinical trials: A systematic review of barriers and interventions CA Cancer J Clin 7178&#x2013;922020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854940</ArticleId><ArticleId IdType="pubmed">33002206</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolich-Zugich J.The twilight of immunity: Emerging concepts in aging of the immune system Nat Immunol 1910&#x2013;192018</Citation><ArticleIdList><ArticleId IdType="pubmed">29242543</ArticleId></ArticleIdList></Reference><Reference><Citation>Denkinger MD, Leins H, Schirmbeck R, et al. HSC aging and senescent immune remodeling Trends Immunol 36815&#x2013;8242015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4710174</ArticleId><ArticleId IdType="pubmed">26611154</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabas-Madrid D, Muniategui A, Sanchez-Caballero I, et al. Improving miRNA-mRNA interaction predictions. BMC Genomics. 2014;15(suppl 10):S2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4304206</ArticleId><ArticleId IdType="pubmed">25559987</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasca D, Diaz A, Romero M, et al. B cell immunosenescence Annu Rev Cell Dev Biol 36551&#x2013;5742020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8060858</ArticleId><ArticleId IdType="pubmed">33021823</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Q, Liu Y, Cheng Y, et al. Diversity and clonal selection in the human T-cell repertoire Proc Natl Acad Sci USA 11113139&#x2013;131442014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4246948</ArticleId><ArticleId IdType="pubmed">25157137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kogut I, Scholz JL, Cancro MP, et al. B cell maintenance and function in aging Semin Immunol 24342&#x2013;3492012</Citation><ArticleIdList><ArticleId IdType="pubmed">22560930</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschi C, Campisi J.Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases J Gerontol A Biol Sci Med Sci 69S4&#x2013;S92014suppl 1</Citation><ArticleIdList><ArticleId IdType="pubmed">24833586</ArticleId></ArticleIdList></Reference><Reference><Citation>Solana R, Tarazona R, Gayoso I, et al. Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humans Semin Immunol 24331&#x2013;3412012</Citation><ArticleIdList><ArticleId IdType="pubmed">22560929</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Micco R, Krizhanovsky V, Baker D, et al. Cellular senescence in ageing: From mechanisms to therapeutic opportunities Nat Rev Mol Cell Biol 2275&#x2013;952020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8344376</ArticleId><ArticleId IdType="pubmed">33328614</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawelec G, Bronikowski A, Cunnane SC, et al. The conundrum of human immune system &#x201c;senescence&#x201d;. Mech Ageing Dev. 2020;192:111357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494491</ArticleId><ArticleId IdType="pubmed">32949594</ArticleId></ArticleIdList></Reference><Reference><Citation>LaPak KM, Burd CE.The molecular balancing act of p16(INK4a) in cancer and aging Mol Cancer Res 12167&#x2013;1832014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944093</ArticleId><ArticleId IdType="pubmed">24136988</ArticleId></ArticleIdList></Reference><Reference><Citation>Reck M, Rodr&#xed;guez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1&#x2013;positive non&#x2013;small-cell lung cancer N Engl J Med 3751823&#x2013;18332016</Citation><ArticleIdList><ArticleId IdType="pubmed">27718847</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok TSK, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial Lancet 3931819&#x2013;18302019</Citation><ArticleIdList><ArticleId IdType="pubmed">30955977</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies Lung Cancer 135188&#x2013;1952019</Citation><ArticleIdList><ArticleId IdType="pubmed">31446994</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial Lancet 3871540&#x2013;15502016</Citation><ArticleIdList><ArticleId IdType="pubmed">26712084</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbst RS, Garon EB, Kim DW, et al. Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro Ann Oncol 29X42&#x2013;X432018</Citation></Reference><Reference><Citation>Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373123&#x2013;1352015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4681400</ArticleId><ArticleId IdType="pubmed">26028407</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non&#x2013;small-cell lung cancer N Engl J Med 3731627&#x2013;16392015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5705936</ArticleId><ArticleId IdType="pubmed">26412456</ArticleId></ArticleIdList></Reference><Reference><Citation>Spigel DR, McCleod M, Jotte RM, et al. Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153) J Thorac Oncol 141628&#x2013;16392019</Citation><ArticleIdList><ArticleId IdType="pubmed">31121324</ArticleId></ArticleIdList></Reference><Reference><Citation>Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial Lancet 389255&#x2013;2652017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6886121</ArticleId><ArticleId IdType="pubmed">27979383</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non&#x2013;small-cell lung cancer N Engl J Med 3771919&#x2013;19292017</Citation><ArticleIdList><ArticleId IdType="pubmed">28885881</ArticleId></ArticleIdList></Reference><Reference><Citation>Faivre-Finn C, Vicente D, Kurata T, et al. Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial Ann Oncol 31S1178&#x2013;S11792020</Citation></Reference><Reference><Citation>Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer N Engl J Med 3782078&#x2013;20922018</Citation><ArticleIdList><ArticleId IdType="pubmed">29658856</ArticleId></ArticleIdList></Reference><Reference><Citation>Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer N Engl J Med 3792040&#x2013;20512018</Citation><ArticleIdList><ArticleId IdType="pubmed">30280635</ArticleId></ArticleIdList></Reference><Reference><Citation>Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC N Engl J Med 3782288&#x2013;23012018</Citation><ArticleIdList><ArticleId IdType="pubmed">29863955</ArticleId></ArticleIdList></Reference><Reference><Citation>Socinski MA, Jotte RM, Cappuzzo F, et al. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) &#xb1; bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. J Clin Oncol. 2018;36 suppl; abstr 9002.</Citation></Reference><Reference><Citation>Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer N Engl J Med 3812020&#x2013;20312019</Citation><ArticleIdList><ArticleId IdType="pubmed">31562796</ArticleId></ArticleIdList></Reference><Reference><Citation>Reck M, Ciuleanu T-E, Dols MC, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. J Clin Oncol. 2020;38 suppl; abstr 9501.</Citation></Reference><Reference><Citation>Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 3642517&#x2013;25262011</Citation><ArticleIdList><ArticleId IdType="pubmed">21639810</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372320&#x2013;3302014</Citation><ArticleIdList><ArticleId IdType="pubmed">25399552</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 3722521&#x2013;25322015</Citation><ArticleIdList><ArticleId IdType="pubmed">25891173</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma N Engl J Med 3781789&#x2013;18012018</Citation><ArticleIdList><ArticleId IdType="pubmed">29658430</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma N Engl J Med 3771824&#x2013;18352017</Citation><ArticleIdList><ArticleId IdType="pubmed">28891423</ArticleId></ArticleIdList></Reference><Reference><Citation>Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma N Engl J Med 3731803&#x2013;18132015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719487</ArticleId><ArticleId IdType="pubmed">26406148</ArticleId></ArticleIdList></Reference><Reference><Citation>Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma N Engl J Med 3781277&#x2013;12902018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5972549</ArticleId><ArticleId IdType="pubmed">29562145</ArticleId></ArticleIdList></Reference><Reference><Citation>Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma N Engl J Med 3801116&#x2013;11272019</Citation><ArticleIdList><ArticleId IdType="pubmed">30779529</ArticleId></ArticleIdList></Reference><Reference><Citation>Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma N Engl J Med 3801103&#x2013;11152019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6716603</ArticleId><ArticleId IdType="pubmed">30779531</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma N Engl J Med 3761015&#x2013;10262017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5635424</ArticleId><ArticleId IdType="pubmed">28212060</ArticleId></ArticleIdList></Reference><Reference><Citation>Galsky MD, Arija J&#xc1;A, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): A multicentre, randomised, placebo-controlled phase 3 trial Lancet 3951547&#x2013;15572020</Citation><ArticleIdList><ArticleId IdType="pubmed">32416780</ArticleId></ArticleIdList></Reference><Reference><Citation>Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma N Engl J Med 3831218&#x2013;12302020</Citation><ArticleIdList><ArticleId IdType="pubmed">32945632</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias R, Giobbie-Hurder A, McCleary NJ, et al. Efficacy of PD-1 &amp; PD-L1 inhibitors in older adults: A meta-analysis. J Immunother Cancer. 2018;6:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885356</ArticleId><ArticleId IdType="pubmed">29618381</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Betzalel G, Steinberg-Silman Y, Stoff R, et al. Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients Eur J Cancer 10861&#x2013;682019</Citation><ArticleIdList><ArticleId IdType="pubmed">30648631</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattar J, Kartolo A, Hopman WM, et al. The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population J Geriatr Oncol 10411&#x2013;4142019</Citation><ArticleIdList><ArticleId IdType="pubmed">30104155</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenstein MRL, Nipp RD, Muzikansky A, et al. Impact of age on outcomes with immunotherapy in patients with non-small cell lung cancer J Thorac Oncol 14547&#x2013;5522019</Citation><ArticleIdList><ArticleId IdType="pubmed">30476576</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: Systematic review and meta-analysis. BMJ. 2018;360:k793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5851471</ArticleId><ArticleId IdType="pubmed">29540345</ArticleId></ArticleIdList></Reference><Reference><Citation>Helissey C, Vicier C, Champiat S.The development of immunotherapy in older adults: New treatments, new toxicities? J Geriatr Oncol 7325&#x2013;3332016</Citation><ArticleIdList><ArticleId IdType="pubmed">27318796</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 37323&#x2013;342015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5698905</ArticleId><ArticleId IdType="pubmed">26027431</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Lancet Oncol 201239&#x2013;12512019</Citation><ArticleIdList><ArticleId IdType="pubmed">31345627</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis JAMA Oncol 51008&#x2013;10192019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487913</ArticleId><ArticleId IdType="pubmed">31021376</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns A, Wei L, Grogan M, et al. Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer J Geriatr Oncol 12813&#x2013;8192021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8184608</ArticleId><ArticleId IdType="pubmed">33627226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis JAMA Oncol 41721&#x2013;17282018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6440712</ArticleId><ArticleId IdType="pubmed">30242316</ArticleId></ArticleIdList></Reference><Reference><Citation>Welaya K, Loh KP, Messing S, et al. Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors J Geriatr Oncol 11523&#x2013;5282020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7805005</ArticleId><ArticleId IdType="pubmed">31175042</ArticleId></ArticleIdList></Reference><Reference><Citation>Muchnik E, Loh KP, Strawderman M, et al. Immune checkpoint inhibitors in real-world treatment of older adults with non&#x2013;small cell lung cancer J Am Geriatr Soc 67905&#x2013;9122019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7814272</ArticleId><ArticleId IdType="pubmed">30698276</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes F, Lorigan P, Woolley S, et al. A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients: The ELDERS study. ESMO Open. 2021;6:100042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7844568</ArticleId><ArticleId IdType="pubmed">33516147</ArticleId></ArticleIdList></Reference><Reference><Citation>Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper Ann Oncol 27559&#x2013;5742016</Citation><ArticleIdList><ArticleId IdType="pubmed">26715621</ArticleId></ArticleIdList></Reference><Reference><Citation>van Holstein Y, Kapiteijn E, Bastiaannet E, et al. Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer Drugs Aging 36927&#x2013;9382019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764930</ArticleId><ArticleId IdType="pubmed">31317421</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline J Clin Oncol 361714&#x2013;17682018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6481621</ArticleId><ArticleId IdType="pubmed">29442540</ArticleId></ArticleIdList></Reference><Reference><Citation>Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 28iv119&#x2013;iv1422017</Citation><ArticleIdList><ArticleId IdType="pubmed">28881921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanesvaran R, Cordoba R, Maggiore R.Immunotherapy in older adults with advanced cancers: Implications for clinical decision-making and future research Am Soc Clin Oncol Ed Book 38400&#x2013;4142018</Citation><ArticleIdList><ArticleId IdType="pubmed">30231397</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari S, Gill AS, Perez CA, et al. Management of immunotherapy toxicities in older adults Semin Oncol 45226&#x2013;2312018</Citation><ArticleIdList><ArticleId IdType="pubmed">30446167</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo C, Serra-Mestres J, Castagna A, et al. Behavioral, psychiatric, and cognitive adverse events in older persons treated with glucocorticoids. Medicines (Basel) 2018;5:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6163472</ArticleId><ArticleId IdType="pubmed">30071590</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyi C, Hellmann MD, Wolchok JD, et al. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2014;2:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4079190</ArticleId><ArticleId IdType="pubmed">24991413</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study J Clin Oncol 293457&#x2013;34652011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624700</ArticleId><ArticleId IdType="pubmed">21810685</ArticleId></ArticleIdList></Reference><Reference><Citation>Felip E, Ardizzoni A, Ciuleanu T, et al. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations Eur J Cancer 127160&#x2013;1722020</Citation><ArticleIdList><ArticleId IdType="pubmed">32028209</ArticleId></ArticleIdList></Reference><Reference><Citation>Marur S, Singh H, Mishra-Kalyani P, et al. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies Semin Oncol 45220&#x2013;2252018</Citation><ArticleIdList><ArticleId IdType="pubmed">30391014</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">28160076</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-7339</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</Title><ISOAbbreviation>Support Care Cancer</ISOAbbreviation></Journal><ArticleTitle>Predictors of the multidimensional symptom experience of lung cancer patients receiving chemotherapy.</ArticleTitle><Pagination><StartPage>1931</StartPage><EndPage>1939</EndPage><MedlinePgn>1931-1939</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00520-017-3593-z</ELocationID><Abstract><AbstractText Label="PURPOSE">Few studies have examined interindividual variability in the symptom experience of lung cancer patients. We aimed to identify the most prevalent, severe, and distressing symptoms, and risk factors associated with increased symptom burden.</AbstractText><AbstractText Label="METHODS">Lung cancer patients (n&#xa0;=&#xa0;145) reported occurrence, severity, and distress for 38 symptoms on the Memorial Symptom Assessment Scale 1&#xa0;week after chemotherapy. Using multidimensional subscales, risk factors for higher global distress, physical, and psychological symptoms were evaluated using simultaneous linear regression.</AbstractText><AbstractText Label="RESULTS">Mean age was 64.0&#xa0;years and 56.6% were female. Mean Karnofsky Performance Status score was 79.1 (SD 14.6) and mean Self-Administered Comorbidity Questionnaire score was 7.3 (SD 3.9). The most distressing and prevalent symptom was fatigue. Problems with sexual interest/activity had the highest mean severity rating. Patients with lower functional status (p&#xa0;=&#xa0;0.001) and higher comorbidity (p&#xa0;=&#xa0;0.02) reported higher global distress. Similarly, lower functional status (p&#xa0;=&#xa0;0.003) and higher comorbidity (p&#xa0;=&#xa0;0.04) were associated with a higher physical symptom burden along with lower body mass index (p&#xa0;=&#xa0;0.02). Higher psychology symptom burden was associated with lower functional status (p&#xa0;=&#xa0;0.01), younger age (p&#xa0;=&#xa0;0.02), non-metastatic disease (p&#xa0;=&#xa0;0.03), higher number of prior treatments (p&#xa0;=&#xa0;0.04), and income (p&#xa0;=&#xa0;0.03).</AbstractText><AbstractText Label="CONCLUSIONS">Fatigue was the most distressing and prevalent symptom among lung cancer patients receiving chemotherapy. Lower functional status was associated with a higher burden of global distress, physical, and psychological symptoms. Younger age and non-metastatic disease were additional risk factors for increased psychological symptoms. Together, these risk factors can help clinicians identify lung cancer patients at increased need for aggressive symptom management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Melisa L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Divisions of Hematology/Oncology and Geriatrics, Department of Medicine, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 505 Parnassus Ave, Mailbox 1270, San Francisco, CA, 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Physiological Nursing, School of Nursing, University of California San Francisco, 2 Koret Way-N631Y, San Francisco, CA, 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Bruce A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Community Health Systems, School of Nursing, University of California San Francisco, 2 Koret Way-N339B, San Francisco, CA, 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunn</LastName><ForeName>Laura B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University, 401 Quarry Road, Stanford, CA, 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammer</LastName><ForeName>Marilyn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Nursing, Mount Sinai Hospital, One Gustave L. Levy Place, Box 1168, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conley</LastName><ForeName>Yvette P</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>School of Nursing, University of Pittsburgh, 440 Victoria Building, 3500 Victoria Street, Pittsburgh, PA, 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Fay</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Nursing, Yale University, PO Box 27399, West Haven, CT, 06516, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Jon D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Oral &amp; Maxillofacial Surgery, University of California San Francisco, 513 Parnassus Ave, San Francisco, CA, 94122, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Louise C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Department of Medicine, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 4150 Clement (181G), San Francisco, CA, 94121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cartwright</LastName><ForeName>Frances</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Nursing, Mount Sinai Hospital and Mount Sinai Queens, One Gustave L. Levy Place, Box 1068, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miaskowski</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physiological Nursing, School of Nursing, University of California San Francisco, 2 Koret Way-N631Y, San Francisco, CA, 94143, USA. chris.miaskowski@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K05 CA168960</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA134900</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000212</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG041180</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NR008346</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Support Care Cancer</MedlineTA><NlmUniqueID>9302957</NlmUniqueID><ISSNLinking>0941-4355</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemotherapy</Keyword><Keyword MajorTopicYN="N">Distress</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Lung cancer</Keyword><Keyword MajorTopicYN="N">Multiple symptoms</Keyword><Keyword MajorTopicYN="N">Symptom burden</Keyword></KeywordList><CoiStatement>Conflicts of interest: The authors have no conflicts of interests to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28160076</ArticleId><ArticleId IdType="mid">NIHMS849542</ArticleId><ArticleId IdType="pmc">PMC5433346</ArticleId><ArticleId IdType="doi">10.1007/s00520-017-3593-z</ArticleId><ArticleId IdType="pii">10.1007/s00520-017-3593-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7&#x2013;30. doi: 10.3322/caac.21332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21332</ArticleId><ArticleId IdType="pubmed">26742998</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvoniemi M, Vasankari T, Loyttyniemi E, Valtonen M, Salminen E. Symptom assessment for patients with non-small cell lung cancer scheduled for chemotherapy. Anticancer Res. 2016;36:4123&#x2013;4128. 36/8/4123.</Citation><ArticleIdList><ArticleId IdType="pubmed">27466520</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr. 2007;37:16&#x2013;21. 2007/37/16.</Citation><ArticleIdList><ArticleId IdType="pubmed">17951226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooley ME. Symptoms in adults with lung cancer. A systematic research review. J Pain Symptom Manage. 2000;19:137&#x2013;153. S0885-3924(99)00150-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10699541</ArticleId></ArticleIdList></Reference><Reference><Citation>Miaskowski C, Cooper BA, Melisko M, Chen LM, Mastick J, West C, Paul SM, Dunn LB, Schmidt BL, Hammer M, Cartwright F, Wright F, Langford DJ, Lee K, Aouizerat BE. Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy. Cancer. 2014;120:2371&#x2013;2378. doi: 10.1002/cncr.28699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.28699</ArticleId><ArticleId IdType="pmc">PMC4108553</ArticleId><ArticleId IdType="pubmed">24797450</ArticleId></ArticleIdList></Reference><Reference><Citation>Miaskowski C, Cooper BA, Paul SM, Dodd M, Lee K, Aouizerat BE, West C, Cho M, Bank A. Subgroups of patients with cancer with different symptom experiences and quality-of-life outcomes: a cluster analysis. Oncol Nurs Forum. 2006;33:E79&#x2013;89. doi: 10.1188/06.ONF.E79-E89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1188/06.ONF.E79-E89</ArticleId><ArticleId IdType="pubmed">16955115</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleeland CS, Mendoza TR, Wang XS, Woodruff JF, Palos GR, Richman SP, Nazario A, Lynch GR, Liao KP, Mobley GM, Lu C. Levels of symptom burden during chemotherapy for advanced lung cancer: differences between public hospitals and a tertiary cancer center. J Clin Oncol. 2011;29:2859&#x2013;2865. doi: 10.1200/JCO.2010.33.4425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2010.33.4425</ArticleId><ArticleId IdType="pmc">PMC3138716</ArticleId><ArticleId IdType="pubmed">21690477</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XS, Shi Q, Lu C, Basch EM, Johnson VE, Mendoza TR, Mobley GM, Cleeland CS. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer. 2010;116:137&#x2013;145. doi: 10.1002/cncr.24703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.24703</ArticleId><ArticleId IdType="pmc">PMC3148693</ArticleId><ArticleId IdType="pubmed">19852033</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc TW, Nickolich M, Rushing CN, Samsa GP, Locke SC, Abernethy AP. What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer. Support Care Cancer. 2015;23:3455&#x2013;3463. doi: 10.1007/s00520-015-2699-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-015-2699-4</ArticleId><ArticleId IdType="pubmed">25791391</ArticleId></ArticleIdList></Reference><Reference><Citation>Tishelman C, Petersson LM, Degner LF, Sprangers MA. Symptom prevalence, intensity, and distress in patients with inoperable lung cancer in relation to time of death. J Clin Oncol. 2007;25:5381&#x2013;5389. 25/34/5381.</Citation><ArticleIdList><ArticleId IdType="pubmed">18048819</ArticleId></ArticleIdList></Reference><Reference><Citation>Brant JM, Beck SL, Dudley WN, Cobb P, Pepper G, Miaskowski C. Symptom trajectories during chemotherapy in outpatients with lung cancer colorectal cancer, or lymphoma. Eur J Oncol Nurs. 2011;15:470&#x2013;477. doi: 10.1016/j.ejon.2010.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejon.2010.12.002</ArticleId><ArticleId IdType="pubmed">21251874</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozachik SL, Bandeen-Roche K. Predictors of patterns ofpain, fatigue, and insomnia during the first year after a cancer diagnosis in the elderly. Cancer Nurs. 2008;31:334&#x2013;344. doi: 10.1097/01.NCC.0000305769.27227.67.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.NCC.0000305769.27227.67</ArticleId><ArticleId IdType="pmc">PMC2663798</ArticleId><ArticleId IdType="pubmed">18772657</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnofsky D, Abelmann WH, Craver LV, Burchenal JH. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer. 1948;1:634&#x2013;656.</Citation></Reference><Reference><Citation>Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003;49:156&#x2013;163. doi: 10.1002/art.10993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10993</ArticleId><ArticleId IdType="pubmed">12687505</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner F, Bachmann LM, Weber U, Kessels AG, Perez RS, Marinus J, Kissling R. Complex regional pain syndrome 1--the Swiss cohort study. BMC Musculoskelet Disord. 2008;9:92. doi: 10.1186/1471-2474-9-92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2474-9-92</ArticleId><ArticleId IdType="pmc">PMC2443796</ArticleId><ArticleId IdType="pubmed">18573212</ArticleId></ArticleIdList></Reference><Reference><Citation>Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A:1326&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pubmed">7999421</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleeland CS, Zhao F, Chang VT, Sloan JA, O'Mara AM, Gilman PB, Weiss M, Mendoza TR, Lee J-W, Fisch MJ. The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer. 2013;119:4333&#x2013;4340. doi: 10.1002/cncr.28376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.28376</ArticleId><ArticleId IdType="pmc">PMC3860266</ArticleId><ArticleId IdType="pubmed">24114037</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright F, D'Eramo Melkus G, Hammer M, Schmidt BL, Knobf MT, Paul SM, Cartwright F, Mastick J, Cooper BA, Chen LM, Melisko M, Levine JD, Kober K, Aouizerat BE, Miaskowski C. Predictors and trajectories of morning fatigue are distinct from evening fatigue. J Pain Symptom Manage. 2015;50:176&#x2013;189. doi: 10.1016/j.jpainsymman.2015.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2015.02.016</ArticleId><ArticleId IdType="pmc">PMC4526314</ArticleId><ArticleId IdType="pubmed">25828559</ArticleId></ArticleIdList></Reference><Reference><Citation>Portenoy RK, Thaler HT, Kornblith AB, McCarthy Lepore J, Friedlander-Klar H, Coyle N, Smart-Curley T, Kemeny N, Norton L, Hoskins W, Scher H. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res. 1994;3:183&#x2013;189. doi: 10.1007/bf00435383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf00435383</ArticleId><ArticleId IdType="pubmed">7920492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie C, Dunn LB, Paul SM, Cooper BA, Skerman H, Merriman JD, Aouizerat B, Alexander K, Yates P, Cataldo J, Miaskowski C. Differences in the symptom experience of older oncology outpatients. J Pain Symptom Manage. 2014;47:697&#x2013;709. doi: 10.1016/j.jpainsymman.2013.05.017. S0885-3924(13)00334-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2013.05.017</ArticleId><ArticleId IdType="pmc">PMC3833968</ArticleId><ArticleId IdType="pubmed">23916681</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12(Suppl 1):4&#x2013;10. 12/suppl_1/4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17573451</ArticleId></ArticleIdList></Reference><Reference><Citation>National Comprehensive Cancer Network.  [Accessed 24 April 2016];NCCN Clinical Practice Guidelines in Oncology: Cancer-related fatigue.  (Version 1.2016)  http://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf.</Citation></Reference><Reference><Citation>Schwartz S, Plawecki HM. Consequences of chemotherapy on the sexuality of patients with lung cancer. Clin J Oncol Nurs. 2002;6:212&#x2013;216. doi: 10.1188/02.cjon.212-216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1188/02.cjon.212-216</ArticleId><ArticleId IdType="pubmed">12087617</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese JB, Shelby RA, Abernethy AP. Sexual concerns in lung cancer patients: an examination of predictors and moderating effects of age and gender. Support Care Cancer. 2011;19:161&#x2013;165. doi: 10.1007/s00520-010-1000-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-010-1000-0</ArticleId><ArticleId IdType="pubmed">20820818</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn KE, Reese JB, Jeffery DD, Abernethy AP, Lin L, Shelby RA, Porter LS, Dombeck CB, Weinfurt KP. Patient experiences with communication about sex during and after treatment for cancer. Psychooncology. 2012;21:594&#x2013;601. doi: 10.1002/pon.1947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pon.1947</ArticleId><ArticleId IdType="pmc">PMC3149787</ArticleId><ArticleId IdType="pubmed">21394821</ArticleId></ArticleIdList></Reference><Reference><Citation>ASCO Institute for Quality Quality Oncology Practice Initiative.  [Accessed 24 April 2016];  http://www.instituteforquality.org/qopi/quality-oncology-practice-initiative-qopi.</Citation></Reference><Reference><Citation>Feliciano J, Gardner L, Hendrick F, Edelman MJ, Davidoff A. Assessing functional status and the survival benefit of chemotherapy for advanced non-small cell lung cancer using administrative claims data. Lung cancer. 2015;87:59&#x2013;64. doi: 10.1016/j.lungcan.2014.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2014.10.011</ArticleId><ArticleId IdType="pubmed">25443272</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457&#x2013;3465. doi: 10.1200/JCO.2011.34.7625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.34.7625</ArticleId><ArticleId IdType="pmc">PMC3624700</ArticleId><ArticleId IdType="pubmed">21810685</ArticleId></ArticleIdList></Reference><Reference><Citation>Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, Bertetto O, Novello S, Migliorino MR, Favaretto A, Spatafora M, Ferrau F, Frontini L, Bearz A, Repetto L, Gridelli C, Barletta E, Barzelloni ML, Iaffaioli RV, De Maio E, Di Maio M, De Feo G, Sigoriello G, Chiodini P, Cioffi A, Guardasole V, Angelini V, Rossi A, Bilancia D, Germano D, Lamberti A, Pontillo V, Brancaccio L, Renda F, Romano F, Esani G, Gambaro A, Vinante O, Azzarello G, Clerici M, Bollina R, Belloni P, Sannicolo M, Ciuffreda L, Parello G, Cabiddu M, Sacco C, Sibau A, Porcile G, Castiglione F, Ostellino O, Monfardini S, Stefani M, Scagliotti G, Selvaggi G, De Marinis F, Martelli O, Gasparini G, Morabito A, Gattuso D, Colucci G, Galetta D, Giotta F, Gebbia V, Borsellino N, Testa A, Malaponte E, Capuano MA, Angiolillo M, Sollitto F, Tirelli U, Spazzapan S, Adamo V, Altavilla G, Scimone A, Hopps MR, Tartamella F, Ianniello GP, Tinessa V, Failla G, Bordonaro R, Gebbia N, Valerio MR, D'Aprile M, Veltri E, Tonato M, Darwish S, Romito S, Carrozza F, Barni S, Ardizzoia A, Corradini GM, Pavia G, Belli M, Colantuoni G, Galligioni E, Caffo O, Labianca R, Quadri A, Cortesi E, D'Auria G, Fava S, Calcagno A, Luporini G, Locatelli MC, Di Costanzo F, Gasperoni S, Isa L, Candido P, Gaion F, Palazzolo G, Nettis G, Annamaria A, Rinaldi M, Lopez M, Felletti R, Di Negro GB, Rossi N, Calandriello A, Maiorino L, Mattioli R, Celano A, Schiavon S, Illiano A, Raucci CA, Caruso M, Foa P, Tonini G, Curcio C, Cazzaniga M. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol. 2005;23:6865&#x2013;6872. 23/28/6865.</Citation><ArticleIdList><ArticleId IdType="pubmed">16192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright F, D'Eramo Melkus G, Hammer M, Schmidt BL, Knobf MT, Paul SM, Cartwright F, Mastick J, Cooper BA, Chen LM, Melisko M, Levine JD, Kober K, Aouizerat BE, Miaskowski C. Trajectories of evening fatigue in oncology outpatients receiving chemotherapy. J Pain Symptom Manage. 2015;50:163&#x2013;175. doi: 10.1016/j.jpainsymman.2015.02.015. S0885-3924(15)00151-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2015.02.015</ArticleId><ArticleId IdType="pmc">PMC4526403</ArticleId><ArticleId IdType="pubmed">25828560</ArticleId></ArticleIdList></Reference><Reference><Citation>Posternak V, Dunn LB, Dhruva A, Paul SM, Luce J, Mastick J, Levine JD, Aouizerat BE, Hammer M, Wright F, Miaskowski C. Differences in demographic, clinical, and symptom characteristics and quality of life outcomes among oncology patients with different types of pain. Pain. 2016;157:892&#x2013;900. doi: 10.1097/j.pain.0000000000000456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000000456</ArticleId><ArticleId IdType="pmc">PMC4939771</ArticleId><ArticleId IdType="pubmed">26683234</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, Beer TM. Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. Cancer. 2008;113:2205&#x2013;2214. doi: 10.1002/cncr.23856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.23856</ArticleId><ArticleId IdType="pmc">PMC3580230</ArticleId><ArticleId IdType="pubmed">18780322</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y, Sakai S. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer. 2001;85:1634&#x2013;1639. doi: 10.1054/bjoc.2001.2162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1054/bjoc.2001.2162</ArticleId><ArticleId IdType="pmc">PMC2363970</ArticleId><ArticleId IdType="pubmed">11742480</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao JJ, Armstrong K, Bowman MA, Xie SX, Kadakia R, Farrar JT. Symptom burden among cancer survivors: impactof age and comorbidity. J Am Board Fam Med. 2007;20:434&#x2013;443. 20/5/434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17823460</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer. 1998;82:1904&#x2013;1908.</Citation><ArticleIdList><ArticleId IdType="pubmed">9587123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurria A, Li D, Hansen K, Patil S, Gupta R, Nelson C, Lichtman SM, Tew WP, Hamlin P, Zuckerman E, Gardes J, Limaye S, Lachs M, Kelly E. Distress in older patients with cancer. J Clin Oncol. 2009;27:4346&#x2013;4351. doi: 10.1200/JCO.2008.19.9463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2008.19.9463</ArticleId><ArticleId IdType="pmc">PMC2799049</ArticleId><ArticleId IdType="pubmed">19652074</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn LB, Aouizerat BE, Cooper BA, Dodd M, Lee K, West C, Paul SM, Wara W, Swift P, Miaskowski C. Trajectories of anxiety in oncology patients and family caregivers during and after radiation therapy. Eur J Oncol Nurs. 2012;16:1&#x2013;9. doi: 10.1016/j.ejon.2011.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejon.2011.01.003</ArticleId><ArticleId IdType="pmc">PMC3115490</ArticleId><ArticleId IdType="pubmed">21324418</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn LB, Cooper BA, Neuhaus J, West C, Paul S, Aouizerat B, Abrams G, Edrington J, Hamolsky D, Miaskowski C. Identification of distinct depressive symptom trajectories in women following surgery for breast cancer. Health Psychol. 2011;30:683&#x2013;692. doi: 10.1037/a00243662011-13463-001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a00243662011-13463-001</ArticleId><ArticleId IdType="pmc">PMC3217116</ArticleId><ArticleId IdType="pubmed">21728421</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz CE, Bode R, Repucci N, Becker J, Sprangers MA, Fayers PM. The clinical significance of adaptation to changing health: a meta-analysis of response shift. Qual Life Res. 2006;15:1533&#x2013;1550. doi: 10.1007/s11136-006-0025-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-006-0025-9</ArticleId><ArticleId IdType="pubmed">17031503</ArticleId></ArticleIdList></Reference><Reference><Citation>Compas BE, Stoll MF, Thomsen AH, Oppedisano G, Epping-Jordan JE, Krag DN. Adjustment to breast cancer: age-related differences in coping and emotional distress. Breast Cancer Res Treat. 1999;54:195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">10445418</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganz PA, Guadagnoli E, Landrum MB, Lash TL, Rakowski W, Silliman RA. Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol. 2003;21:4027&#x2013;4033. doi: 10.1200/JCO.2003.08.097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2003.08.097</ArticleId><ArticleId IdType="pubmed">14581426</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayvergia N, Shah PC, Denlinger CS. Survivorship in non-small cell lung cancer: Challenges faced and steps forward. JNCCN. 2015;13:1151&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5450910</ArticleId><ArticleId IdType="pubmed">26358799</ArticleId></ArticleIdList></Reference><Reference><Citation>Miaskowski C, Dunn L, Ritchie C, Paul SM, Cooper B, Aouizerat BE, Alexander K, Skerman H, Yates P. Latent class analysis reveals distinct subgroups of patients based on symptom occurrence and demographic and clinical characteristics. J Pain Symptom Manage. 2015;50:28&#x2013;37. doi: 10.1016/j.jpainsymman.2014.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2014.12.011</ArticleId><ArticleId IdType="pmc">PMC4492860</ArticleId><ArticleId IdType="pubmed">25647419</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>